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The genes of TRP channel subunits are expressed in many tissues. I identified transcripts of 
Trpc1 and Trpv6 in bone. In order to understand their function in bone, I studied the bone 
phenotype in mice lacking Trpc1 (Trpc1-/-), in mice carrying a non-functional mutation of Trpv6 
(Trpv6mt/mt), in mice carrying both mutations and in wild-type mice. To this aim, I had first to 
establish µCT measurements using femur as a long bone and to determine age-dependent 
changes of femurs from wild-type mice on a C57BL/6 ("B6") and on a 129SvJ/C57BL/6 
("mixed") genetic background to exclude genetic heterogeneity, which might affect the bone 
phenotype. Femur length was shorter, endocortical volume was reduced and cross-sectional 
thickness was increased in Trpv6mt/mt mice whereas the bone volume fraction, mineral density 
and thickness of trabecular bone was reduced in Trpc1-/- mice. In the double mutant mice, the 
cortical bone phenotype of Trpv6mt/mt mice was not compensated by the deletion of Trpc1 
whereas the effect of Trpc1 deletion on trabecular bone was compensated by the Trpv6 
mutation.  
I also established a femur fracture model, set up a tasklist for analyzing the callus formation 
by µCT and used a three-point bending test to estimate the biomechanical stiffness of the 
femur. Mineralization of callus was increased in Trpv6mt/mt mice but I did not observe any 
difference in stiffness comparing all four mouse strains.  
Because of the positive bone phenotype of Trpc1-/- mice, I examined osteoclasts and 
osteoblasts isolated/differentiated from bone marrow cells and bone pieces for Trpc1 
expression. Both cell types were positive. In order to visualize Trpc1 expressing cells and to 
delete Trpc1 in a cell-specific way, I generated two novel mouse strains from scratch by 
homologous recombination: A Trpc1-IRES-Cre mouse strain and a "floxed" Trpc1 mouse strain. 
Pups of both stains are available and with Trpc1-IRES-Cre strain, we already visualized Trpc1 
expressing cells in various tissues including bone. Together with the Trpc1 "global" knockout 
mice (studied for their bone phenotype), the two novel Trpc1 strains allow dissecting Trpc1 






Die Gene von TRP-Kanal Untereinheiten werden in vielen Geweben exprimiert. Ich habe Trpc1 
und Trpv6 Transkripte in Knochen identifiziert. Um deren Funktion im Knochen zu verstehen, 
habe ich den Knochenphänotyp von Mäusen, denen das Trpc1-Gen (Trpc1-/-) fehlt, Mäusen 
die eine Kanal-inaktivierte Mutation von Trpv6 (Trpv6mt/mt) aufweisen, Mäusen welche beide 
Mutationen aufweisen  (Trpc1-/-/ Trpv6mt/mt) und Wildtyp Mäuse untersucht. Für dieses Ziel 
musste ich zuerst µCT Messungen, unter der Verwendung von Femur als Röhrenknochen, 
etablieren, sowie die altersabhängigen Veränderungen der Femora von Wildtyp Mäusen und 
die genetische Heterogenität, die den Knochenphänotyp betreffen könnte, bei Mäusen mit 
einem C57BL/6 („B6”) sowie einem 129SvJ/C57BL/6 („gemischtem”) genetischen Hintergrund, 
bestimmen. Der Femur von Trpv6mt/mt Mäusen war kürzer, das endokortikale Volumen 
reduziert und die Dicke des Querschnitts erhöht. Da waren bei Femora von Trpc1-/--Mäusen 
der Anteil des Knochen Volumens, die Mineraldichte und die Dicke der Trabekel vermindert 
im Vergleich zu Femora. Bei den Mäusen mit Doppelmutation wurde der kortikale 
Knochenphänotyp von Trpv6mt/mt  Mäusen nicht durch die Deletion von Trpc1-/- kompensiert, 
wohingegen der Effekt der Trpc1-/- Deletion auf den trabekulären Knochen durch die Mutation 
von Trpv6  kompensiert wurde. 
Gleichzeitig habe ich ein Frakturmodell des Femurs etabliert, eine Tasklist entwickelt zur 
Analyse der Kallusbildung mittels µCT und einen 3-Punkt-Biegeversuch angewendet, um die 
biomechanische Steifheit des Femur einzuschätzen. Die Mineralisierung des Kallusgewebes 
bei Trpv6mt/mt Mäusen war erhöht, allerdings konnte ich beim Vergleich aller vier Mauslinien 
keine Unterschiede in der Steifheit feststellen. 
Wegen des eindeutigen Knochenphänotyps bei Trpc1-/- Mäusen, habe ich Osteoklasten und 
Osteoblasten isoliert bzw. differenziert aus Knochenmarkzellen und Knochenstückchen auf 
Trpc1-Expression untersucht. Beide Zelltypen waren positiv. Um Trpc1-exprimierende Zellen 
sichtbar zu machen und um Trpc1 zellspezifisch auszuschalten, habe ich zwei neue Mauslinien 
mittels homologer Rekombination von Grund auf neu hergestellt: Eine Trpc1-IRES-Cre 
Mauslinie und eine „gefloxte“ Trpc1 Mauslinie. Die Nachkommen beider Linien sind verfügbar 
und mit der Trpc1-IRES-Cre Linie haben wir bereits Trpc1 exprimierende Zellen in mehreren 





verfügbaren Trpc1 „globalen“ Knock-out Linie (die ich im Hinblick auf einen möglichen 
Knochenphänotyp untersucht habe), erlauben die zwei neuen Trpc1 Linien die Trpc1 Funktion 







Bone is a dynamic tissue organized as a framework to form a skeletal system in organisms. 
The skeleton plays several significant roles in the body such as protection e.g. the skull 
protects the brain, movement and locomotion, e.g. the organisms move due to the 
coordinated function of bone and muscles, and reservoir, such as the bones serve as a storage 
unit for minerals like calcium, phosphate and magnesium. In bone, principally there are two 
main cell types: Bone forming osteoblasts and bone resorbing osteoclasts, which work in a 
balanced fashion to maintain normal bone structure (Allen and Burr, 2014). The skeleton is 
continuously changing under the effects of modelling and remodeling processes (Katsimbri, 
2017). Modelling includes the change in shape or size of bones mostly occurring early in 
development, for instance during growth of long bones. On the other hand, remodeling 
involves the maintenance of the structure of bones throughout the lifespan due to the 
coordinated activity of osteoblasts and osteoclasts (Kobayashi et al., 2003).  
1.1.1  Osteoblasts 
Osteoblasts are specialized bone-forming cells located on the outer surfaces of bone and 
within the bone cavities and derived from pluripotent mesenchymal stromal cells (Katsimbri, 
2017). Various signaling pathways, for instance, a Wnt signaling pathway (Day et al., 2005) and 
proteins such as bone morphogenetic proteins (BMP) (Cao and Chen, 2005) play a vital role in 
osteoblasts differentiation and function. The Wnt signaling pathway, which activates ß-
catenin (canonical Wnt signaling pathway) leads to the up-regulation of transcriptional 
factors, required for differentiation and maturation of osteoblasts and ultimately increases 
bone mass (Monroe et al., 2012). The process for the formation of osteoblasts is called 
osteoblastogenesis. They start to build up the bone by the synthesis and secretion of type-I 
collagen and other, mostly non-collagenous specialized extracellular matrix proteins, which 
form the unmineralized organic matrix called osteoid. It serves as a template for osteoblasts 
to deposit minerals in the form of hydroxyapatite crystals leading to the formation of bone. A 
fraction of osteoblasts remains in the osteoid and are known as osteocytes (Katsimbri, 2017). 





bone. The remainder 60-80% of the cells undergo apoptosis after completing the process of 
bone formation.   
1.1.2  Osteoclasts 
Osteoclasts are large multinucleated cells derived from mononuclear precursor cells of the 
monocyte macrophage lineage capable of resorbing the bone (Teitelbaum and Ross, 2003). 
The differentiation process of osteoclasts from their precursor cells, known as 
osteoclastogenesis, primarily depends on two important cytokines namely CSF-1 (colony 
stimulating factor 1) and RANKL (receptor activator of nuclear factor NF-B ligand) (Yoshida 
et al., 1990), which signal through c-fms (the receptor of macrophage colony stimulating 
factor, M-CSF) and RANK, respectively (Katsimbri, 2017). Resorption of bone starts when 
mature osteoclasts adhere to the bone surface and become polarized to produce villus-like 
projections (podosomes) and distinct membrane domains, the sealing zone (SZ), the ruffled 
border (RB) and the functional secretory domain (FSD) (Katsimbri, 2017) (Figure 1-1). The SZ 
provides firm adhesion of the osteoclasts to the bone surface and isolates the acidic 
environment required for resorption from the neighboring bone matrix. Osteoclasts then start 
secreting several acids such as citric, hydrochloric and lactic acids at the RB in a tightly closed 
compartment to resorb the bone (Luxenburg et al., 2007) and proteolytic enzymes such as 
Cathepsin K (Cat K) for degradation (Yamaza et al., 1998). After degradation, the degraded 
collagen as well as mineral residues such as Ca2+ and PO4+ are phagocytosed by the osteoclasts 
and either get dissolved by lysosomes or enter the functional secretory domain (Nesbitt and 
Horton, 1997) eventually being released into the blood stream by the process termed as 
transcytosis. After completing the bone resorption process, osteoclasts undergo apoptosis 
(programmed cell death) due to increased extracellular Ca2+ levels. Dysregulation of 
osteoclasts such as increased activity may lead to a condition known as osteoporosis, whereas 






Figure 1-1 Bone resorption by an osteoclast. Schematic representation of a resorbing 
multinucleated osteoclast illustrating the sealing zone (SZ), ruffled border (RB) and the 
functional secretory domain (FSD). It resorbs the bone surface and forms a Howship lacuna by 
the secretion of ions (H+ and Cl-) and the proteolytic enzyme Cathepsin K (Cat K). The bone 
degradation products are phagocytosed by osteoclasts and either degraded by lysosomes or 
released into the blood stream by the process of transcytosis. [Source: Figure adapted from the 
original in Basic and Applied Bone Biology, Editors David B.Burr, Mathew R. Allen] 
1.1.3  The bone remodeling cycle 
The bone remodeling cycle (Figure 1-2) can be classified into five different stages, activation, 
resorption, reversal, formation and termination (Katsimbri, 2017). At the end of this 
physiological cycle, total bone volume does not alter, but the old bone get replaced by a newly 
formed one (Andersen et al., 2009). This cycle is very crucial in maintaining the mechanical 
integrity of bones by replacing the old or damaged bone with a new healthier one. The cells 
responsible for bone remodeling i.e. osteoclasts and osteoblasts are arranged in a temporary 
anatomical cascade known as a basic multicellular unit (BMU) and the duration of the BMU is 
known as the bone remodeling period, which could last for several months.    
1 Activation: It is the first stage of a cycle which involves the recruitment of osteoclast 
precursors to form fully functional multinucleated osteoclasts. The remodeling initiating 
signals either hormonal or mechanical are assessed by bone. Hormones such as 
parathyroid hormone (PTH) and estrogen released in response to systemic changes, 
mechanical stress and micro-damage to the skeleton, are considered as triggering signals 
to osteocytes (Bonewald, 2007). The PTH binds with PTH-receptors present on the surface 
of osteoblasts and stromal cells, which activates the expression of RANKL and M-CSF that 





2 Resorption: Mature multinucleated osteoclasts digest the bone by the combined action of 
proteolytic enzymes (Bouillon and Prodonova, 2000) and acid secretion (Kornak et al., 
2001). Functional osteoclasts secrete H+ and Cl- ions in a sealed vicinity, which lowers the 
pH to 4.5 to degrade the bony surface by dissolution, thus exposing them to the matrix 
metalloproteinase enzymes such as Cat K. The resultant pits are known as Howship 
lacunae (Lüllmann-Rauch, 2012). After resorption, osteoclasts undergo apoptosis thus 
terminating this phase (Katsimbri, 2017).  
3 Reversal: It is the least well understood phase of the cycle and is described by the 
termination of resorption and initiation of a bone formation phase, which involves the 
recruitment of cells such as monocytes and pre-osteoblasts required for the bone 
formation (Everts et al., 2002). The exact coupling signals that link the bone resorption and 
formation phases are not clear, however it is proposed that transforming growth factor-ß 
(TGF-ß) interferes with the production of RANKL by osteoblasts, thus inhibiting pre-
osteoclasts from differentiating into functional cells; ultimately decreasing bone 
resorption (Katsimbri, 2017). Osteoclasts are then replaced by osteoblast-lineage cells to 
initiate the bone formation. Mononuclear cells present in the pre-formed cavities deposit 
mucopolysaccharide-rich material such as osteopontin that serves as a cement line 
between the new and old bone (Andersen et al., 2013). 
4 Formation: During this stage, osteoblasts lay down an unmineralized organic matrix called 
osteoid, primarily composed of type I collagen, which serves as a template to form mature 
bone after deposition of minerals over time. Some osteoblasts get buried within the newly 
formed osteoid also known as osteocytes. This phase lasts for several months (Katsimbri, 
2017).  
5 Termination: This is the final step of the remodeling cycle that involves the mineralization 
of osteoid and takes place over 90 and 130 days in the case of trabecular and cortical 
bones, respectively. It involves the deposition of hydroxyapatite crystals along with small 
amounts of acid phosphate, carbonate and magnesium. After mineralization, the bone 






Figure 1-2 Bone remodeling cycle. A sequential schematic representation of five stages of the 
bone remodeling cycle is shown. Following microdamage or another trigger, a portion of bone 
in a resting phase enters into the first stage, activation, where pre-osteoclasts start 
accumulating over the surface of old bone followed by the second stage, resorption, polarized 
multi-nucleated osteoclasts engulf the bone and form resorption pits where pre-osteoblasts 
migrate to replace the osteoclasts in a reversal phase. In the fourth stage, formation, 
osteoblasts generate bone, and subsequently minerals (Ca2+,PO4+) and hydroxyapatite crystals 
are deposited and a compact new bone is formed in the final stage, termination. The bone 
thus enters into the resting phase again. [Source: Figure adapted from the original in Agents Affecting 
Mineral Ion Homeostasis and Bone Turnover in Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 
12th Edition]    
1.1.4  Bone fracture 
Bone fractures either due to severe mechanical traumas such as accidents, falls and sport 
injuries, or spontaneously in a disease state called osteoporosis. It causes anatomical 
discontinuity of a bone structure and inability to withstand mechanical load efficiently. Bone 
fractures can be broadly classified into two main types: 
1. Open fracture: Along with bone, there is damage to surrounding soft tissue including skin 





2. Closed fracture: In this case, breaking of a bone occurs internally while the skin remains 
intact. 
It is a common problem, which affects all age groups ranging from infants to elderly people. 
Over the recent years, incidence of osteoporotic or fragility fractures have become a serious 
issue worldwide. According to the International Osteoporosis Foundation (IFO), the annual 
number of osteoporotic fractures in the European Union (EU) will rise from 3.5 million in 2010 
to 4.5 million in 2025, with an approximate incidence increase of 28% (Hernlund et al., 2013). 
Therefore, new therapeutic advancements are in high demand to aid the fracture healing 
process. 
1.1.4.1 Bone fracture healing 
Bone fracture healing is a complex series of events where the bone heals without the 
formation of scar tissue. Although it is a natural process, various biophysical, biomechanical 
and pharmaceutical interventions may aid in rapid healing (Casanova et al., 2014). Biophysical 
approaches such as ultrasound, shockwaves and electromagnetic field simulations help in 
bone anabolism or formation (Aaron et al., 2006). Mechanical interventions include the usage 
of screws, metal plates etc. to stabilize the broken ends of a bone for proper healing (Histing 
et al., 2011). The goal of medicaments is to accelerate the healing process and strengthening 
the callus tissue for the union of broken ends. The process of fracture healing can be divided 
into four different overlapping stages (Figure 1-3) (Schindeler et al., 2008): 
a. Inflammation: Excessive trauma leading to a bone fracture causes the disruption of 
the vascular supply and therefore a hypoxic condition arises in this region. Due to 
decreased local oxygen levels and nutrients, macrophages leucocytes and other 
inflammatory cells such as granulocytes, lymphocytes and monocytes migrate in this 
region to resist infections and also leads to the formation of a hematoma (Schindeler 
et al., 2008). A wide range of cytokines and growth factors like transforming growth 
factor-ß (TGF-ß), platelet derived growth factor (PDGF), macrophage colony 
stimulating factor (M-CSF), bone morphogenetic proteins (BMPs) and tumor necrosis 
growth factor-α (TNF-α) are also secreted in this region (Einhorn, 1998), (Bolander, 
1992). These factors cause the migration of multipotent mesenchymal stem cells which 
play a significant role in repair and subsequently bone formation (Shapiro, 2008).  This 





surrounding tissues and muscles mainly provide mechanical support to the broken 
structure.  
b. Soft callus (fibrocartilage) formation: During this stage, the hematoma formed is 
replaced by a fibro-vascular tissue, which is rich in chondrocytes and fibroblasts 
(Schindeler et al., 2008). Proliferation of chondrocytes and fibroblasts are stimulated 
by the coordinated activity of growth factors like TGF-ß, PDGF, insulin like growth 
factor (IGF) and BMPs (Gerstenfeld et al., 2003), (Ai-Aql et al., 2008). Chondrocytes and 
fibroblasts synthesize the cartilaginous matrix, mainly composed of collagen type II 
and fibrous tissue respectively to form a fibrocartilaginous, semi-rigid soft tissue 
between the broken ends to provide some mechanical stability (Barnes et al., 1999). 
However, at this stage the callus cannot withstand any significant amount of load and 
is inclined to re-fracture when exposed to trauma. Cartilaginous callus is deprived of 
vascular system at this stage, which develops later in the woven bone.  The soft callus 
serves as a template for bony callus formation at later stages. 
 
Figure 1-3 Stages of fracture healing. Schematic representation of overlapping stages of the 
bone healing process is shown. (a) Inflammation, upon fracture vascular supply disrupts and 
a hematoma is formed followed by (b) soft callus formation: periosteal (external) and 
endosteal (internal) soft calluses are formed, which serve as the template for (c) hard callus 
formation, osteoblasts generate spongy or woven bone having better biomechanical 
properties than soft callus and finally (d) remodeling: to convert the woven bone into a 
lamellar (healed) bone also known as bony callus by the combined activity of osteoclasts and 
osteoblasts. [Source: Figure taken from Anatomy and Physiology by Rice University, author/publisher 
OpenStax, available online on BCCampus] 
c. Hard callus formation: This stage also known as primary bone formation and is the 
most active energy demanding stage of fracture repair and is characterized by a higher 





collagen, alkaline phosphatase and osteocalcin in the bloodstream (Gerstenfeld et al., 
2003). Osteoprogenitors differentiate into osteoblasts, in the presence of certain 
osteogenic factors (Gerstenfeld et al., 2003) and members of the BMP family (Chen et 
al., 2004), (Nakase and Yoshikawa, 2006) generate woven bone matrix. The 
osteoprogenitors originate from variable sources such as from local surrounding 
tissues (Rumi et al., 2005) or the circulation (Eghbali-Fatourechi et al., 2005). The 
woven bone or hard callus has better mechanical stability compared to the 
fibrocartilage (Casanova et al., 2014). 
d. Bone remodeling: This is the final stage of fracture repair also known as secondary 
bone formation where the shape of bone and vascular system prior to fracture is 
restored (Gerstenfeld et al., 2003). It is a similar to the remodeling procedure where 
osteoclasts and osteoblasts work in an organized fashion to maintain the bone 
integrity. Here lamellar bone replaces the woven or spongy bone and the mechanical 
strength is also restored. 
1.1.4.2   Evaluation of fracture healing 
Assessment of fracture healing is a very challenging task, as callus is a complex structure 
consisting of different type of cells and tissues that change over time. The extent and quality 
of fracture healing can be assessed by both structural and biomechanical evaluations. In 
animal models, structural evaluations involve both non-invasive methods like radiography, 
micro-magnetic resonance imaging (micro-MRI) and micro-computed tomography (µCT) 
(Morgan et al., 2009) and invasive methods like histology (Epari et al., 2010). Radiography is 
the most direct and robust way of analyzing the fracture of a bone. In the early stages of 
fracture healing, micro-MRI can be used to evaluate the quantity as well as the quality of 
fibrocartilage tissue. However, this method has a disadvantage that strong magnetic 
radiations interfere with the healing process itself (Casanova et al., 2014). Over the last 
decade, µCT has emerged as a powerful tool to determine the callus microarchitecture. It not 
only provides information about the callus volume but also gives an estimation about the 
mechanical strength of the newly formed bone (Morgan et al., 2009), (Shefelbine et al., 2005). 
Most recently, Raman imaging and small-angle X-ray scattering (SAXS) have been used to 
evaluate the direction of collagen fibers, an indication of newly formed bone (bony callus) and 





In biomechanical evaluations, varying degrees of load are applied to estimate the stress 
bearing capacity of a healed bone. In vitro three-point and four-point bending tests provide 
estimation of bending stiffness of fractured bones, an in vivo method especially suitable for 
long bones. Nanoindentation (Leong and Morgan, 2008) and scanning acoustic microscopy 
(SAM) (Eckardt and Hein, 2001) are also used for the assessment of callus biomechanical 
properties. In nanoindentation, a diamond tip is inserted into a specimen up to a certain depth 
and mechanical properties are estimated depending on the resistance of the tissue to the 
applied forces.  In contrast, using SAM, mechanical properties or strength are estimated by 
the reflection of acoustic (sound) waves after hitting the callus tissue. 
1.1.4.3 Micro-computed tomography (µCT) 
The µCT enables to understand the bone microarchitecture by determining cortical and 
trabecular parameters, estimating the bone mineral density (Bouxsein et al., 2010) and 
prediction of biomechanical properties of intact and fractured bones (Shefelbine et al., 2005). 
It has become a valuable tool nowadays in the field of bone biology, which works on the 
principle of taking X-ray projected images of an object at different angles and mathematically 
converting them into 3-dimentional (3D) images.  
 
Figure 1-4 Basic operational principle of µCT scanning system. Schematic representation of a 
µCT scanner with all components is shown. An X-ray source emits radiation which passes 
through the filter to strike the object i.e. bone placed inside the sample holder rotating at an 
angle and subsequently projected X-rays are detected by the detector. The detector transfers 
the signal to an attached computer system to produce a resultant stack of 3D images using 
mathematical algorithms. [Source: Guidelines for assessment of bone microstructure in 






The bone is placed in an object holder and then X-rays emitted from a radiation source passes 
through a filter (aluminum or copper) and finally strike the rotating object. The resultant 
images fall on the detector attached to the computer that converts the stack of signals into 
3D images by using mathematical algorithms. With the in vitro scanning system, the object is 
continuously moving at a defined angle while the X-ray source and detector remains 
stationary. Such systems are used for analysis for explanted organs such as femurs, teeth etc. 
In an in vivo scanning system, contrary to in vitro scanners the bone remains stationary while 
camera/detector revolves around the object used for imaging live animal models (Helfrich, 
2012). 
1.2 Transient Receptor Potential (TRP) channels 
The TRP channels were first discovered in fruit-fly Drosophila melanogaster photoreceptors in 
which a spontaneous mutation caused a transient potential, instead of a sustained potential, 
upon steady light stimulation (Cosens and Manning, 1969). Twenty years later, the mutation 
responsible for this transient potential was identified by Montell and Rubin (Montell and 
Rubin, 1989) and the underlying gene dubbed “transient receptor potential” or “trp”. Later in 
1995, the first mammalian TRP cDNA i.e. TRPC1 was cloned (Zhu et al., 1995), (Wes et al., 
1995). Since then TRP channels have been extensively studied to determine their potential 
role in mammalian physiology as well as pathology. The TRP cation channel family comprises 
of 28 mammalian (27 human) members and has been classified into six subfamilies based on 
their sequence similarities (Nilius and Owsianik, 2011). The six subfamilies include TRPC, 
where C stands for “canonical” which comprises of seven members i.e. TRPC1-C7, TRPV, with 
V for “vanilloid” comprises of six members i.e. TRPV1-V6, TRPM, with M for “melastatin” 
contains eight members i.e. TRPM1-M8, TRPP, with P for “polycystin” has three members 
namely TRPP2, TRPP3 and TRPP5, TRPML, with ML for “mucolipin” has also three members 
being TRPML1-ML3 and the last group TRPA has only one member TRPA1, with A for “ankyrin” 
(Figure 1-5 a). All members of this superfamily share a similar characteristic of having six 
transmembrane domains (TM1-TM6) flanked by cytosolic N (amino) and C (carboxy) termini 
(Figure 1-5 b). The cation permeable pore region of TRP proteins resides within the TM5-TM6 
linkers. Four TRP proteins co-assemble to form a tetrameric channel. For example, TRPC4 can 
form homotetrameric TRPC4 channels or heterotetrameric TRPC4/TRPC1, TRPC5/TRPC1 or 





depending on their amino acid sequences and the length of the N and C termini (Nilius and 
Flockerzi, 2014a, b). The structures of more than ten TRP channel complexes have been solved 
by X-ray crystallography and cryo electron-microscopy (Cryo-EM) (Madej and Ziegler, 2018).    
 
Figure 1-5 The Transient Receptor Potential (TRP) channel superfamily. (a) The classification 
of TRP channels into six subfamilies based on their amino acid sequence similarity i.e.  TRPC 
(seven members, C1-C7), TRPM (eight members, M1-M8), TRPV (six members, V1-V6), TRPML 
(three members, ML1-ML3), TRPA (one member), TRPP (three members, P2-P3 and P5) and 
two pore channels (TPC1 and TPC2) are shown. (b) Scheme of a single TRP protein/subunit 
consisting of six transmembrane domains (1-6) flanked by cytoplasmic N-, C-termini, and the 
pore region permeable to cations (Ca2+ and Na+) is present in between the transmembrane 
domains 5 and 6.   
The majority of TRPs are known to act as non-selective cation channels, permeable to both 
Ca2+ and Na+ ions. Exceptions include TRPV5 and TRPV6, which are highly Ca2+ selective and 
TRPM4 and TRPM5 being highly Na+ selective (Nilius and Flockerzi, 2014a, b). The channels 
are activated by different mechanisms such as temperature change (heat or cold stimulus), 
pH change and by certain agonists and antagonists via secondary messengers (Freichel et al., 
2012).  
1.2.1  Functional diversity of TRP channels 
TRP-deficient mouse models have been generated by manipulating the Trp genes in 
embryonic stem (ES) cells using homologous recombination to identify their role in normal 
physiological as well as pathological conditions. They play a significant role from embryonic 





temperature, reproduction, metabolic and neuronal pathways, memory and taste perception 
(Nilius and Flockerzi, 2014a, b). For instance, Trpm7 is of fundamental significance during 
embryonic development and Trpm7-/- embryos cannot survive more than eight days of 
embryogenesis (Jin et al., 2012). Conversely, deletion at adulthood causes 
macrothrombocytopenia (Jin et al., 2008). Studies have also shown lethal embryonic effects 
of the deletion of Trpm6 (Walder et al., 2009) and Trpp2 (Wu et al., 1998). Trpc1-deficient 
mice have shown increased body weight (Dietrich et al., 2007 and own results) and decreased 
salivary secretions (Liu et al., 2007). The significance of Trpv6 in reproduction was determined 
by Weissgerber et al. in 2011, i.e. deletion of Trpv6 leads to impaired male fertility and 
decreased Ca2+ absorption from intestine (Weissgerber et al., 2012), (Weissgerber et al., 
2011). Other members of the TRPV family such as TRPV1 act as thermosensors and 
nocisensors, whereas TRPV4 is involved in maintenance of systemic osmoregulation as well as 
neuro-inflammation (Flockerzi and Nilius, 2007). Trpm5 KO mouse models have shown 
reduced insulin secretion and thus elevated blood glucose levels (Brixel et al., 2010), (Colsoul 
et al., 2010). TRPA1 has been recognized as a sensor for the environmental stimuli such as 
cold, itch and pain (Nilius and Flockerzi, 2014a, b). Approximately 20 hereditary diseases in 
humans related to diverse fields such as cardiology, nephrology, pulmonology, urology etc. 
are linked to or caused by mutations of 12 Trp genes.    
1.2.2  Transient Receptor Potential Canonical 1 (TRPC1)  
The transient receptor potential canonical 1 (TRPC1) belongs to the subfamily of TRPC 
channels. Trpc1 was the first mammalian Trp cDNA to be cloned (Wes et al., 1995), (Zhu et al., 
1995) however the exact mechanism for the activation of this channel is still a matter of 
debate (Dietrich et al., 2014). TRPC channels are activated following phospholipase C (PLC) 
stimulation by Gq-coupled receptors (GqCR) or receptor tyrosine kinase (RTK) activation by 
certain agonists (Nilius and Flockerzi, 2014a, b). The Trpc1 gene, which encodes TRPC1 protein, 
is located on chromosome 3 and 9 in the human and mouse genomes, respectively. The gene 
consists of 13 distinct exons while the initiation codon for the translation of the protein is 
present within exon one (Nilius and Flockerzi, 2014a, b). Until now, Trpc1 reportedly translates 
into five different splice variants in humans and seven in rodents (mice) according to the 





The TRPC1 protein is predicted to have six transmembrane domains (TM1 to TM6) flanked by 
cytosolic C- and N-termini (Wes et al., 1995), (Zhu et al., 1995). In 2004, Dohke et al. postulated 
that TM5 and TM6 are involved in the formation of the ion conducting pore region of the 
channel (Dohke et al., 2004). It also shows highest amino acid sequence similarity with the 
other members of its family like TRPC2, TRPC4 and TRPC5 (Flockerzi and Nilius, 2007). 
Although TRPC1 is the founding member of this superfamily, sufficient data to support that it 
could form a functional homomeric channel is still lacking. It interacts with other members of 
its subgroup such as TRPC4 and TRPC5 channel subunits to form heteromeric TRPC1/TRPC4, 
TRPC1/TRPC5 and TRPC1/TRPC4/TRPC5 channels (Broker-Lai et al., 2017) For instance, co-
expression of TRPC1 with TRPC4 or TRPC5 in HEK293 cells, leads to the formation of functional 
heterotetrameric channels as indicated by specific current-voltage (IV) relationship in 
comparison to the IV-relationship of homomeric TRPC5 channels (Beck et al., 2017). It has also 
been shown that TRPC1 may interact with other proteins such as TRPV4, TRPV6 and TRPP2 
(Nilius and Flockerzi, 2014a, b) and both ORAI and STIM proteins (Ambudkar, 2014).  
Transcripts of Trpc1 are expressed in many cells and tissues such as brain, heart, and kidney 
(Nilius and Flockerzi, 2014a, b) and it has been postulated that Trpc1 gene is ubiquitously 
expressed throughout the body (Wes et al., 1995), (Zhu et al., 1995). This assumption is 
difficult to prove considering that there are no reliable ion currents detectable or suitable 
antibodies available. Dietrich et al. have generated Trpc1-deficient mice (Dietrich et al., 2007).  
Most information about the physiological functions of TRPC1 derived from experiments 
performed on those Trpc1-deficient mice, which lack TRPC1 throughout the organism. Lack of 
TRPC1 has been associated with changes of cardiovascular, central nervous, skeletal and 
immune functions (Dietrich et al., 2014). It has also been associated with pathologic conditions 
such as diabetic nephropathy (Zhang et al., 2009), Parkinson’s disease (Mattson, 2012), Darier-
White disease (Pani and Singh, 2008) and Huntington’s disease (Wu et al., 2011). 
1.2.3  Transient Receptor Potential Vanilloid 6 (TRPV6) 
The TRPV6 channel belongs to the subfamily of TRPV channels, encoded by the gene Trpv6 
located on chromosomes 7q33-q34 and 6 in the human and mouse genomes respectively. The 
Trpv6 gene contains 15 exons and 14 introns, which spans over a region of ≈15.7 kb (Hirnet et 
al., 2003). According to the Ensemble genome browser, Trpv6 has three splice variants to date 





detected in uterus, placenta, pancreas, prostate, parts of the digestive system (oesophagus, 
stomach, duodenum and colon) and kidney by RT-PCR and northern blot analyses in mouse 
tissues (Hirnet et al., 2003), (Weissgerber et al., 2011), (Lehen'kyi et al., 2012). Trpv6 
transcripts along with transcripts of its closest relative Trpv5, have also been identified in 
human and mouse bone and osteoclasts. Nijenhuis et al. have shown the expression of Trpv6 
in bone marrow cells (Nijenhuis et al., 2003). Trpv6 mRNA has been also detected in murine 
syncytiotrophoblasts (Wissenbach et al., 2001) and uterus (Moreau et al., 2002).  
TRPV6 and its closest relative TRPV5 are the only highly Ca2+-selective channels in the TRP-
superfamily (Peng et al., 1999), (Wissenbach et al., 2001). In normal physiological conditions, 
TRPV6 conducts only Ca2+ ions but in their absence it can also conducts monovalent cations 
like Na+ (Voets et al., 2003), (Wissenbach et al., 2001). TRPV6 proteins co-assemble to form 
homotetrameric channels (Saotome et al., 2016) while heterotetrameric TRPV5/TRPV6 
channels might occur after heterologous expression of TRPV6/TRPV5 cRNAs in oocytes 
(Hoenderop et al., 2003). TRPV6 also shows interaction with other proteins such as TRPC1 
(Schindl et al., 2012), (Courjaret et al., 2013) and calmodulin (Niemeyer et al., 2001). TRPV6 
becomes inactivated by various compounds such as Xestospongin C (Vassilev et al., 2001), 
Ruthenium red and certain anti-fungal drugs like econazole and miconazole (Hoenderop et al., 
2001).  
As for many other TRP proteins, the information about the physiological functions of TRPV6 
has been gathered mainly from Trpv6-deficient (Bianco et al., 2007) (Weissgerber et al., 2011) 
or Trpv6-mutant mouse lines (Weissgerber et al., 2012). Mice lacking functional TRPV6 are 
viable but they have shown compromised body weight and reduced femoral length and 
mineral density (Bianco et al., 2007) as well as decreased fertility (Weissgerber et al., 2012), 
(Weissgerber et al., 2011). In 2011, van der Eerden et al. showed reduced cortical and 
endocortical volume in Trpv6 mutated mice compared to wild-type animals. The role of TRPV6 
channel in prostate, breast, colon, ovarian, and thyroid gland cancers has been extensively 
studied by various research groups (Nilius and Flockerzi, 2014a, b). Trpv6 transcripts are 
overexpressed in prostate cancer (Wissenbach et al., 2001) as well as breast cancer (Lehen'kyi 
et al., 2012) and the expression pattern correlates with the severity of the disease; especially 





significance of Trpv6 in carcinogenesis and might serve as a suitable marker for detection as 
well as a potential therapeutic target.   
1.3 Targeted modification of TRP channel genes 
Gene deficient mouse models have contributed significantly in understanding the functional 
significance of TRP channels (Flockerzi and Nilius, 2007). The classical way is to replace the 
chromosomal regions by targeted homologous recombination and thereby the gene of 
interest either can be disrupted to obtain classical/constitutive “knockout” or modified by the 
insertion of additional gene cassettes comprising of fluorescent reporter genes to obtain 
“knock-in” mouse models (Joyner, 2005).   
1.3.1 Classical gene targeting 
Constitutive knockout mouse models have been widely used for the functional 
characterization of TRP channels such as Trpc1-/- (Dietrich et al., 2007) and Trpv6-/- 
(Weissgerber et al., 2011) mouse models. This approach has several limitations such as 
potential embryonic lethality, if the gene of interest such as Trpm6 (transient receptor 
potential melastatin 6) or Trpm7 being essential for embryogenesis is ablated: The embryos 
mostly die at embryonic day 12.5 (Walder et al., 2009). Another drawback especially 
associated with the widely expressed genes, is the determination of cell- or organ-specific role 
of them, since it is almost impossible to distinguish cell-autonomous effects from effects 
resulting from other tissues or organs.   
1.3.2 Conditional gene targeting 
Conditional gene targeting describes a type of gene targeting where manipulation of a 
particular gene of interest is carried out in a defined population of cells or in an organ at a 
specific time-point, using a cell-specific recombinase system (Joyner, 2005), (Albert et al., 
1995).  
Cre-loxP and Flp-FRT are the two types of site-specific recombinase systems mostly used for 
generating conditional gene targeting (Joyner, 2005). The Cre-loxP system, derived from 
bacteriophage P1, is a robust system that requires three components for functioning: Cre 
recombinase, loxP target sites and mono/di-valent ions. No additional cofactors and accessory 





superfamily that cleaves the DNA segment flanked by loxP sites. The target site for the Cre 
enzyme is loxP or “locus of crossing over x at bacteriophage P1” (Sternberg et al., 1981). A lox 
P site comprises of 34 base pairs with an eight bp non-palindromic core region flanked by a 13 
bp palindromic region. The loxP site is commonly represented by a triangle and the direction 
of the triangle depicts the outcome of the recombination reaction like deletion (floxing a 
gene), inversion and translocation of that specific DNA sequence (Hoess et al., 1982), (Figure 
1-6). The Flp-FRT system is analogous to the Cre-loxP system.       
 
Figure 1-6 The Cre-loxP recombinase system. Schematic representation of DNA 
recombinations i.e. (a) deletion, (b) inversion and (c) translocation of a gene of interest 
between heterologous chromosomes upon Cre mediated excision, (black triangle depicts loxP 














Aims of study 
1. TRPC1 and TRPV6 proteins are expressed in bone cells but the exact role of these 
proteins in bone homeostasis and fracture healing is not known. The first aim was to 
establish µCT for the precise determination of cortical trabecular and callus 
parameters of bone. Using this method, I wanted to elucidate the role of TRPC1 and 
TRPV6 in bone microarchitecture using Trpc1 or Trpv6 gene-deficient and Trpc1/Trpv6 
double mutant mouse strains. Additionally, I correlated the µCT results with 
biomechanical properties of Trpc1 or Trpv6 gene-deficient bones using three-point 
bending tests. At the cellular level, I compared in vitro osteoclasts differentiation 
between Trpc1-deficient and wild-type mice. 
 
2. As the cellular expression of Trpc1 is hard to analyze due to missing appropriate 
antibodies for immunohistochemistry it is still an open debate where exactly TRPC1 
proteins occur in mice. Therefore, the second aim was the generation of a Trpc1-IRES-
Cre mouse line where Cre recombinase is present in all Trpc1 expressing cells. After 
crossing with reporter mouse strains such as eRosa26-GFP, Trpc1-positive cells are 
easily detectable by their fluorescence. This mouse line will help to visualize and to 
analyze the expression of Trpc1 in bone as well as all over the mouse body. 
 
3. The TRPC1 protein seems to be present in different bone cells such as osteoclasts and 
osteoblasts. Using global Trpc1-deficient mice, it is difficult to rule out the role of Trpc1 
specifically in bone, as one cannot exclude any interfering effects from the TRPC1 
present in other cells or organs. To attribute a phenotype to a certain cell type it is 
necessary to use a conditional knockout mouse strain. Therefore, the third aim of my 
doctoral research was the generation of a conditional Trpc1–flox mouse strain. After 
crossing these mice with a cell-specific Cre mouse strain, it will be possible to 
determine TRPC1 function in the desired cell type or organ.




2 Materials and Methods 
2.1 Bone analyses 
2.1.1 General materials 




α-MEM (Minimal Essential 
Medium) 
gibco by Life Technologies (22561-
021) 
FBS  gibco by Life Technologies (10270-
106) 
Heparin (Heparin-Natrium) 5000 
iE/mL 
Braun GmbH 
Antibiotic antimycotic solution Sigma-Aldrich (A5955) 
Recombinant Mouse M-CSF    R&D systems (416-ML-010) 
Recombinant Mouse 
TRANCE/TNFSF11/RANK L     
R&D systems (462-TEC-010) 
 
TRACP & ALP double stain kit  TaKaRa Bio Inc. (MK300) 
Bovine Serum Albumin Sigma-Aldrich (A4503) 
Osteo Assay Stripwell plate Corning Inc. (3989) 
Fracture 
model 
Surgical instruments  Fine Science Tools GmbH, Heidelberg 
Tungsten guide wire (0.2 mm)  RISystem (RIS.521.100) 
Mouse screw RISystem (RIS.221.100) 
Hand-drill 2-1mm  RISystem (RIS.390.130) 
Square box wrench 0.50 mm RISystem (RIS. 590.111) 
Suture (Surgicryl) 3/8 circle  Smi (11151519) 
asid-med, hair removing cream Aisd-Bonz (NDXZ10) 
Dexpanthenol 5% (BEPANTHEN®) Bayer (3400935940179) 
Carprofen 50 mg/mL (RIMADYL®) Zoetis Inc. 
Ketaminhydrochlorid 100 mg/mL 
(URSOTAMIN®) 
Serumwerk Bernburg AG 
Xylazinhydrochlorid 23.32 mg/mL  
2% (ROMPUM®) 
Bayer  
0.9% NaCl  B.Braun 
Glucose 5% B.Braun 
2.1.2  Mice 
All animal experiments have been reviewed and approved by the responsible authority, the 
local ethics committee of the Saarland. We abide by the 3R principle (replacement, reduction, 
refinement). Four independent mouse strains were used in the bone related experiments: 
Wild-type, Trpc1-/- (Dietrich et al., 2007), Trpv6mt/mt (Weissgerber et al., 2012) and double 




mutant mice i.e. Trpc1-/-/Trpv6mt/mt (generated by breeding of Trpc1-/- and Trpv6mt/mt mice). To 
get mice of a defined mixed genetic background all of the above mentioned genotypes were 
obtained by specific breeding of a 129SvJ with a C57BL/6 mouse. The resulting pups, the F1 
generation were used for all experiments as “mixed” (129SvJ/C57BL/6). Mice were under a 12 
h light/dark cycle with food and water ad libitum. All animals had the same genetic background 
i.e. mixed strain (129SvJ/C57BL/6). Only male mice were used in experiments at ages ranging 
from 2 to 24 weeks.   
2.1.3  Methods 
2.1.3.1 Primary osteoclast culture 
The primary osteoclasts culture protocol was established in our laboratory by modifying the 
original method published by van der Eerden et al. (van der Eerden et al., 2005). Mice were 
sacrificed by cervical dislocation and bones (femurs and tibiae) were freed from muscles and 
surrounding soft tissues. Bones were cut at the distal end to make an opening, fixed within a 
small piece of microfluidic tubing and finally placed in a 1.5 mL eppendorf tube containing 250 
µL mouse osteoclast culture (MOC) medium. The composition of MOC medium: Minimum 
essential medium with nucleosides (alpha-MEM) supplemented with 10% FBS, 170 IE/mL 
heparin. Hundred U/mL penicillin, 100 µg/mL streptomycin, 250 ng/mL amphotericin B were 
added as antibiotic/antimycotic solution. The tubes were centrifuged at 4500 rpm for 3 min 
to thoroughly flush out the bone marrow cells. The cell pellet was re-suspended in 750 µL 
medium and transferred to a Falcon tube containing 9 mL culture medium. The cells were 
centrifuged at 4°C for 5 min at 410 g followed by resuspension of the pellet in 1 mL medium 
and 9 mL lysis buffer and subsequent incubation for 5 min at 21°C. Thereafter, cells were 
centrifuged at 410 g for 5 min at 4°C and the cell pellet was washed (220 g for 5 min) twice 
with 5 mL MOC medium. Finally, the cells were counted using Neubauer’s chamber (Blau 
Brand) and seeded at a concentration of 1x105 cells per well (total volume per well was 150 
µL) in an Osteo Assay Stripwell plate in the presence of 30 ng/mL M-CSF and 20 ng/mL RANKL. 
Every 2-3 days, approximately two-thirds of culture medium was replaced by freshly prepared 
MOC medium containing both growth factors and 85 µL of 6N HCl/50 mL medium. Eight days 
later, culture medium was aspirated and attached cells were washed once with 1xPBS (Sigma-
Aldrich) and stained for tartrate-resistant acid phosphatase (TRAP) activity as per 
manufacturer’s instructions (TaKaRa). TRAP served as a marker for osteoclasts. The von Kossa 




staining was performed to determine the resorption capability of osteoclasts after visualizing 
the pits and trails formed. 
For using the TRACP & ALP double stain kit, cells were fixed by adding 50 µL fixation solution 
(provided by the manufacturer) to each well and incubated for 5 min at 21°C. Wells were 
washed twice with deionized water and then TRAP solution was added containing 0.1 volume 
of sodium tartrate as per manufacturer’s guidelines. The wells were incubated for 40 min at 
37°C for the enzymatic reaction to take place. The enzymatic activity was stopped by adding 
deionized water and subsequently wells were washed three times with the deionized water. 
TRACP-positive red/pink colored cells, containing more than three nuclei were considered as 
mature osteoclasts. Those cells were counted manually using a microscope (Zeiss Axiovert 40 
CFL, Carl Zeiss AG) at a magnification of 10x and in parallel representative images were taken 
by a camera (Zeiss AxioCam MRC5, Carl Zeiss AG).   
For von Kossa staining, all reagents were prepared fresh prior to use. The culture medium was 
removed and wells were washed three times with deionized water followed by incubation for 
30 min with 5% AgNO3 in bright light. The wells were washed three times with deionized water 
and incubated for 2 min with 5% Na2CO3 (in 25% formalin). The reaction was stopped by 
washing three times with deionized water and subsequently 5% Na2S2O3 was added for two 
minutes. At the end, the wells were washed again three times with deionized water and 
observed with a microscope (Zeiss Stemi 2000-C, Carl Zeiss AG) at a magnification of 1.6x and 
in parallel representative images were taken by a camera (Zeiss AxioCam MRC5, Carl Zeiss AG). 
The unstained surface (resorbed areas) was quantified using ImageJ (Version 1.51f) available 
online.     
2.1.3.2 RT-PCR from crushed bone and bone cells 
Total RNA from the crushed femurs and in vitro cultured osteoclasts and osteoblasts was 
isolated using the RNeasy Micro Kit (Qiagen). Total RNA (0.5 µg) was reverse transcribed using 
the Maxima first strand cDNA synthesis kit (ThermoFisher Scientific) as per the manufacturer’s 
guidelines. One µL of cDNA was used in RT-PCR reaction for the detection of Trpc1 transcripts 
using a primer set (Forward primer: 5’-TGCAAACGTTCTGAGTTACC-3’ and a reverse primer: 5’-
GGTTGTGATTGTGCTGACG-3’) covering sequences from exons 9 to11. The composition of 
reaction mixture:   




Component (reagent) Quantity (µL) Final concentration 
First strand (cDNA) 1 variable 
5x Phusion buffer HF 5 1x 
10 mM dNTP’s 0.5 200 µM 
2U/µL DNA polymerase 0.5 1 U 
10 µM forward primer 1.5 0.5 µM 
10 µM reverse primer 1.5 0.5 µM 
Deionized H2O ad 25  
 
RT-PCR conditions were as follows: initial denaturation for 30 s at 98°C, 35 amplification cycles 
(10 s at 98°C, 20 s at 64°C, 15 s at 72°C), and a final extension for 5 min at 72°C using a phusion 
high fidelity polymerase (ThermoFisher scientific) in a 25 µL reaction volume. The resultant 
product was loaded onto a 2% agarose standard gel (Roth) and separated by electrophoresis 
along with a GeneRuler 1Kb plus DNA ladder as marker (ThermoFisher scientific) to estimate 
the size of the amplified DNAs. 
2.1.3.3 Fracture model 
All mice used in this experiment were handled with great care according to the animal welfare 
and ethical norms. The surgical procedure as described by Herath and coworkers (Herath et 
al., 2015) was approved by the responsible authority of the Saarland. Twenty-week-old male 
mice were weighed and anesthetized by administering 100 mg/kg body weight (BW) ketamine 
and 10 mg/kg BW xylazine intraperitoneally. Under aseptic conditions, a 5 mm medial 
parapatellar incision was performed on the right knee to dislocate the patella laterally. After 
drilling a 0.5 mm diameter hole into the intercondylar notch, an injection needle (27G 3/4˝, 
0.4x19 mm) was inserted through the intramedullary canal followed by a 0.2 mm tungsten 
guidewire coming out from the proximal side of the femur. A simple, transverse mid-shaft 
fracture (according to AO classification) was produced using a blunt guillotine. A weight of 80 
g was dropped from a height of 100 mm in the middle of femoral shaft and afterwards the 
broken ends were stabilized using a 17.2 mm stainless steel mouse screw (RISystem). Wound 
closure was carried out using 4-0 synthetic absorbable sutures. Bone fracture and subsequent 
screw implantation was controlled at various steps by radiography (MX-20, Faxitron X-ray 
Corp., Wheeling, IL, USA) (Figure 2-1).  Five mg/kg BW carprofen was injected subcutaneously 
prior to the surgical procedure and the following day. Carprofen is a nonsteroidal anti-
inflammatory and analgesic drug. All animals were housed in separate cages with ad libitum 
excess to food and water and a standard cycle of 12 h of light and dark each for four weeks. 




Wound status was carefully monitored daily during the first week and then once per week 
until four weeks.  
 
Figure 2-1 Fracture model at surgery day. Representative X-ray images taken at three 
different steps of surgical procedure at day zero: (a) Arrow-head indicates the fracture site 
and a guidewire passing through the bone; (b) insertion of a screw following a guidewire to 
hold the broken ends and (c) fractured femur stabilized by a screw.  
After four weeks, mice were weighed again and wound status, activity, and gait pattern was 
carefully examined. The mice were sacrificed by cervical dislocation and an X-ray image of the 
broken bone was taken for the preliminary estimation of bone healing (Figure 2-2). 
Afterwards, both healthy and fractured femora were removed and freed from muscles and 
surrounding tissue. The screw was explanted using a square box wrench. Biomechanical 
testing was performed by a non-destructive three-point bending test. Finally, bones were 
wrapped in a 0.9% NaCl soaked gauze or wet tissue paper and preserved at -80°C for callus 
analysis by µCT. 
 
Figure 2-2 Fracture model after 27 days. Representative X-ray image taken at day 28 after 
fracture, arrow-head shows broken ends joined together by the callus formation. 




2.1.3.4  Bone biomechanics 
The femurs were mounted on a three-point bending device (Mini Zwick Z 2.5, Zwick GmbH) 
for estimation of the bending stiffness (N/mm) using a non-destructive bending test. The 
protocol followed the procedure described by Herath and coworkers (Herath et al., 2015). The 
bones were placed horizontally on two lower posts 6 mm apart, with the condyles facing 
upwards. A gradually increasing load at a rate of 1 mm/min was applied in the middle of the 
femoral shaft by the upper post (Figure 2-3) and displacement plotted versus applied load (N) 
was displayed using the software testXpert V12.0 on a computer system attached with a 
three-point bending device.  The application of force was manually stopped as soon as the 
displacement curve deviated slightly from the linearity. Finally, bones were wrapped within 
0.9% NaCl soaked gauze and frozen at -80°C for µCT analysis. The bending stiffness (L/D) 
(N/mm) was calculated as the slope of the linear portion of the load versus displacement 
curve:  
Bending stiffness (N/mm) = y2-y1/x2-x1, where x (x2-x1) is the displacement (D) in mm and y 
(y2-y1) is the load (force) applied in Newton, N. 
 
Figure 2-3 Biomechanical testing. (A) The three-point bending device (Mini Zwick Z 2.5) is 
shown with a femur lying horizontally on two lower posts 6 mm apart while a force is applied 
vertically from the upper post. The image is taken of the instrument (Mini Zwick Z 2.5) that is 
present in the Institut für Klinisch-Experimentelle Chirurgie, Universität des Saarlandes, 
Homburg. (B) Load/force-displacement curve. 




2.1.3.5  Bone analysis by µCT 
Intact/healthy and fractured femurs from male mice were removed and thoroughly cleaned 
from the surrounding muscles. All bones were scanned at a resolution of 6.5 µm using a high 
resolution scanning system SkyScan 1172 µCT (Bruker MicroCT, Kontisch, Belgium). The bones 
were wrapped in a wet tissue paper, placed in a plastic holder and mounted vertically in the 
sample chamber for imaging. The scanning conditions were adjusted according to the 
previously published guidelines by M. L. Bouxsein (Bouxsein et al., 2010). X-ray source voltage 
and current were 50 kV and 200 µA, respectively. Beam hardening was reduced using a 0.5 
mm aluminum filter. The exposure time was five seconds and scanning angular rotation was 
set to 180° with an increment of 0.4 rotation step (deg). NRecon (version 1.6.10.6) software 
was used to reconstruct the images while other software such as DataViewer (1.5.1.2) and 
CtAn (1.16.4.1+) were used for bone analysis (all provided by Bruker MicroCT).   
Projection images obtained after scanning the bone samples were converted into 
tomographic cross-sectional images using NRecon software. All datasets were reconstructed 
under the same conditions. Misalignment compensation was always used as automatically 
estimated by the software and smoothing and ring artifact reduction were set at levels 2 and 
5, respectively. A 20% correction in beam hardening was performed to sharpen the resultant 
cross-sectional images. After reconstruction, 3D femurs were oriented in the desired direction 
using a software DataViewer.  
DataViewer was used to direct the reconstructed cross-sections of a dataset in a fixed/defined 
orientation for consistent analysis of the individual bones. By comparing three different views 
i.e. coronal, transaxial and sagittal views, displayed in DataViewer, the bone dataset was 
oriented in an upright position displayed in the coronal view keeping the femoral head 
upwards while in a transaxial view, the intersecting lines were kept exactly in the middle of 
the growth-plate cross-section (Figure 2-4). In this way, all samples have similar orientations, 
which is important for selecting a similar volume of interest (VOI) for cortical and trabecular 
analysis of each bone using CtAn software. 





Figure 2-4 Orientation of a 3D femur using a DataViewer software. Representative images 
depict three different views of a reconstructed 3D femur dataset i.e. coronal, transaxial and 
sagittal views. 3D femur appears straight with a femoral head on the top in a coronal view. In 
a transaxial view, the representative cross-section is oriented so that the intersecting lines are 
exactly in the middle of four semi-circular islands. 
After orientation, the dataset was uploaded in CtAn software to determine the bone 
parameters. For determining the cortical and trabecular parameters, the first step was to 
determine the volume of interest (VOI) for both cortical and trabecular bone analyses 
(Bouxsein et al., 2010). The center of the femoral shaft was used as a reference for selecting 
cortical bone VOI, whereas the trabecular bone VOI was selected with reference to the growth 
plate (van der Eerden et al., 2012) (Figure 2-5).  





Figure 2-5 Selection of volume of interest (VOI) for cortical and trabecular analysis of femurs 
from 12- (left panel) and 24-week- (right panel) old mice. (Aa, Ba) For cortical bone analysis, 
the central dotted white line in the femoral shaft is considered as a reference, 25 cross-
sections (6.5 µm each) are analyzed above and below this reference to determine the cortical 
bone parameters. For trabecular bone analysis, the reference for defining VOI is adapted 
according to the original method defined in the Bruker-microCT application note (Micro-CT 
analysis of mouse long bones (proximal tibia, distal femur)) as follows: Moving slice-by-slice 
towards the growth plate from the condyles, a point is reached where a clear “bridge” of low 
density cartilage (chondrocyte seam) is established from one corner of the cross-section to 
another. As soon as this bridge starts to disappear, that particular cross-section is taken as a 
landmark. This landmark defines the reference section, RS, at position 0, (indicated as 1, in 
red), trabecular VOI is then defined relative to this reference section, at section 100 (RS+100, 
2), 150 (RS+150, 3), 300 (RS+300, 4) and 350 (RS+350, 5) (Ab, Bb). For 12-week-old mice, 
sections between 1 and 3 are considered as offset (150 cross-sections), while VOI lies within 
the sections 3 and 5 (150 cross-sections). For 24-week-old mice, sections between 1 and 2 are 
taken as offset (100 cross-sections), while VOI consists of the sections 2 and 4 (200 cross-
sections) as indicated by red lines and the corresponding cross-section.   




For the cortical bone analysis, the reference was selected exactly in the middle of the femur 
shaft by dividing the total number of cross-sections by two and then twenty-five cross-sections 
above and below this reference were taken as VOI. A total of fifty cross-sections of 6.5 µm 
each were analyzed to determine the cortical bone parameters such as cortical bone volume 
(BV), endocortical volume (Ec.V), cross-sectional thickness (Cs.Th), and perimeter using a 
special tasklist (supplementary Table 6-1) in the supplement. Cortical tissue mineral density 
(TMD) was estimated using calcium hydroxyapaptite (CaHA) phantoms of known densities i.e. 
0.25 and 0.75 g/cm3 (Bouxsein et al., 2010) following a Bruker-microCT method note (Bone 
mineral density (BMD) and tissue mineral density (TMD) calibration and measurement   by 
micro-CT using Bruker-MicroCT CT-Analyser) and a special tasklist (supplementary Table 6-2) 
in the supplement. 
For the trabecular bone analysis, the cross-section where the chondrocyte seam, a low density 
cartilage ‘bridge’, separating the four islands started to disappear was selected as a reference 
section or landmark (Figure 2-5). Moving away from this landmark towards the diaphysis, the 
region including the growth plate and primary spongiosa in the metaphysis was excluded as 
offset (Figure 2-5). Selection of an appropriate VOI for the trabecular bone analyses in mouse 
femur bone is crucial, because trabecular region is located adjacent to the metaphyseal 
growth plate. Selecting a VOI too close to the growth plate will cause contamination of primary 
spongiosa or extending too far from the growth plate will leads to the inclusion of empty 
spaces i.e. tissue volume, subsequently reducing the bone volume fraction (BV/TV). Moreover, 
trabecular bone is constantly changing with age, which highlights the need of selecting 
appropriate trabecular bone VOI depending on the age of mice being analyzed. A total number 
of 150 and 200 cross-sections in the region of the secondary or mature spongiosa for 12- and 
24-week-old mice respectively were used to determine trabecular bone parameters using a 
special tasklist (supplementary Table 6-3) in the supplement. These parameters include 
trabecular number (Tb.N), trabecular thickness (Tb.Th), trabecular separation (Tb.Sp) and 
trabecular pattern factor (Tb.Pf). Trabecular separation is the mean distance between the 
trabeculae whereas trabecular pattern factor is inverse index of connectivity between the 
trabeculae. Trabecular bone mineral density (BMD) (includes both bony- and non-bony-
voxels) was also estimated by comparing the dataset with CaHA phantoms in a similar fashion 
as tissue mineral density, however a separate tasklist was used (supplementary Table 6-4) in 
the supplement. Two different threshold ranges i.e. 120-255 and 80-255, estimated by the 




Otsu method of thresholding (Manual for Bruker-microCT CT-Analyser v.1.13, The user’s 
guide), were utilized for cortical and trabecular bone analyses, respectively. All four tasklists 
were modified from the original that were kindly provided by Dr. Bram van der Eerden, 
Erasmus Medical Centre, Rotterdam.  
For the callus tissue analysis, the steps such as scanning, reconstruction and orientation of 
fractured femur bones were performed exactly in the same aforementioned manner. After 
loading the dataset in CtAn, the VOI was selected based on the presence of callus tissue. The 
VOI contained all cross-sections comprising the callus tissue i.e. newly formed tissue (bone) 
surrounding the fracture site. For ROI selection, endosteal and periosteal callus region was 
manually selected by eliminating the cortical bone from the surrounding callus tissue 
(Casanova et al., 2016). (Figure 2-6). Total callus volume, volume of low and highly mineralized 
bony callus were determined using various threshold values such as 68-255 (total volume), 
68-97 (low mineralized callus) and 98-255 (highly mineralized callus) respectively (Bosemark 
et al., 2013), (Orth et al., 2017). As callus is a newly formed bone tissue, trabecular parameters 
such as Tb.N, Tb.Th, Tb.Sp and Tb.Pf were determined to estimate the callus microarchitecture 
(Casanova et al., 2016), (Kondo et al., 2015) using an independent tasklist (supplementary 
Table 6-5) in the supplement. This special tasklist for callus analysis modified from the original 
that was kindly provided by Dr. Robert Tower (MacKay Orthopedic Research Laboratory, 
Perelman, School of Medicine, University of Pennsylvania, USA). 
 
Figure 2-6 Selection of VOI and ROI for callus analysis. (a) Representative X-ray image shows 
the explanted fractured femur after removal of the screw; two dotted lines indicate the VOI 
i.e. all cross-sections containing the callus tissue while the central line represents (b) a cross-
sectional image (6.5 µm) wherein periosteal and endosteal callus ‘ROI’ has been selected 
manually (highlighted in red color) delineating the cortical bone (grey) for callus analysis. 




2.2 Targeted modification of the mouse Trpc1 gene 
2.2.1 General materials 
2.2.1.1  List of enzymes 


























Phusion high fidelity 
DNA polymerase 
M0530 
*All enzymes were purchased from New England BioLabs® (NEB, Ipswich, Massachusetts, USA), HF means     
High-Fidelity 
2.2.1.2  List of kits 
Kits Supplier (catalog number) 
GenElute plasmid miniprep kit Sigma-Aldrich (PLN350) 
Promega PureYield plasmid maxiprep 
System 
Promega (A2393) 
Qiagen plasmid Plus maxi kit  Qiagen (12963) 
High pure PCR product purification kit Roche Life Science (11732676001) 
Transcriptor first strand cDNA synthesis kit Roche Life Science (04896866001) 
RNeasy micro kit (50) Qiagen (74004) 




Megaprime DNA Labeling System, dNTP GE Healthcare (RPN1605) 
Wizard SV gel and PCR clean up system Promega (A9281) 
 
2.2.1.3  Oligodeoxyribonucleotide primers 
All oligodeoxyribonucleotide primers were purchased from Sigma-Aldrich in a lyophilized form 
and stored at -20°C until use. Stock solution (100 µM) was prepared by dissolving DNA in 
deionized water as per the manufacturer’s instructions and stored at -20°C. Working solution 
of 10 µM was used in all experiments. The name, sequence (5’-3’), melting temperature (Tm), 
forward (F) or reverse (R) orientation and application/purpose of the respective 
oligodeoxyribonucleotide primers is listed in tables below (Table 2-1 to Table 2-5)  
Table 2-1 Oligodeoxyribonucleotides for the generation of the Trpc1-IC targeting vector and 
















60 F Amplification of 3´2 with AflII site 
CM_84 CTTAAGGCTACACAGAGAAACCC
TGT 
60 F Amplification of 3´2 with AflII site  
CM_85 CTTAAGCCTTTCATCTGATTTTGT
AACC 
60 R Amplification of 3´2 with AflII site  
CM_86 CTTAAGACAGGGTTTCTCTGTGTA
GC 
60 R Amplification of 3´2 with AflII site 
CM_87 CCATAAGGGATCTCAGAAAGG 62 F Amplification of 3’1 probe (IC) 
CM_88 ACCTCTTGTCTATCTTTTGGC 60 R Amplification of 3’1 probe (IC) 
CM_89 GGCATTTGAAACTCAGTCCC 60 F Amplification of 3’2 probe (IC) 
CM_90 CAGAGGAAGTCCTCTGTCC 60 R Amplification of 3’2 probe (IC) 
CM_91 AGGCATACCTTTGGGTTAGG 60 F Amplification of 3’3 probe (IC) 
CM_92 CAGGCTCAACTTAAAATTCATC 60 R Amplification of 3’3 probe (IC) 
CM_93 TAGAATTATGCTTGTGTCAACC 60 F Amplification of 3’4 probe (IC) 
CM_94 GTTGCTAAATCATAACTTCATCC 62 R Amplification of 3’4 probe (IC) 
CM_95 GCATAATAAATGTTAAGAAGTGC 60 F Amplification of 5’1 probe (IC) 
CM_96 AGTGTAAAGGCTGTTCTAAGTTC 60 R Amplification of 5’1 probe (IC) 
CM_97 TCTATTCTAGTCCTCCTGCC 60 F Amplification of 5’2 probe (IC) 
CM_98 GGTGGGTCACTTAGGAAGAC 62 R Amplification of 5’2 probe (IC) 
CM_99 CAACAACAAATACGAGGAGATG 62 F Amplification of 5’3 probe (IC) 
CM_100 ATCCTATAGGTAAAGATGATGAA 60 R Amplification of 5’3probe  (IC) 
CM_101 CCAGTGCATTAAGGAAAATGTG 62 F Amplification of 5’4 probe (IC) 
CM_102 GAAGAGGAATTAGCCCTAAAAG 62 R Amplification of 5’4 probe (IC) 




CM_103 CGCGTCTTAAGTAGTAGATCC 62 F Sequencing 5’Homology (IC) 
CM_104 GGATCTACTACTTAAGACGCG 62 R Sequencing 5’Homology (IC) 
CM_105 CCTGAAGGCTGAAGTAGAGG 62 F Sequencing 5’Homology (IC) 
CM_106 CCTCTACTTCAGCCTTCAGG 62 R Sequencing 5’Homology (IC) 
CM_107 GCTGTGATTGTTGGAACTTAC 60 F Sequencing 5’Homology (IC) 
CM_108 GTAAGTTCCAACAATCACAGC 60 R Sequencing 5’Homology (IC) 
CM_109 CCTCATTCTTACTATGTAGCTG 62 F Sequencing 5’Homology (IC) 
CM_110 CAGCTACATAGTAAGAATGAGG 62 R Sequencing 5’Homology (IC) 
CM_111 CTAGGGAAAACAGAATTCCCT 60 F Sequencing 5’Homology (IC) 
CM_112 AGGGAATTCTGTTTTCCCTAG 60 R Sequencing 5’Homology (IC) 
CM_125 CCATAACAGATCTGAAAGACTG 62 F Sequencing 3’Homology (IC) 
CM_126 CAGTCTTTCAGATCTGTTATGG 62 R Sequencing 3’Homology (IC) 
CM_127 CACAGAGAAATCCTGTCTTGG 62 F Sequencing 3’Homology (IC) 
CM_128 CCAAGACAGGATTTCTCTGTG 62 R Sequencing 3’Homology (IC) 
CM_129 GGTTTCCCAGCTGTCGCATG 64 F Sequencing 3’Homology (IC) 
CM_130 CATGCGACAGCTGGGAAACC 64 R Sequencing 3’Homology (IC) 
CM_131 CCATGTAGGGACTAAATTGAG 60 F Sequencing 3’Homology (IC) 
CM_132 CTCAATTTAGTCCCTACATGG 60 R Sequencing 3’Homology (IC) 
CM_133 GCGCCAAGATCTGTCAAAATT 60 F Sequencing pAR_9 (IC) 
CM_134 GGCTTCGGCCAGTAACGTTA 62 R Sequencing pAR_9 (IC) 
CM_135 GGCTTCTGAGGCGGAAAGA 60 F Sequencing pAR_9 (IC) 
CM_136 GCAAGTATGCAAATACAGTCT 58 R Sequencing pAR_9 (IC) 
CM_137 CGCCGGATCTGATATCATCG 62 F Sequencing pKO.ICF 
CM_138 CGATGATATCAGATCCGGCG 62 R Sequencing pKO.ICF 
CM_139 TAACGTTACTGGCCGAAGCC 62 F Sequencing pKO.ICF 
CM_140 CACGGGGACGTGGTTTTCC 62 F Sequencing pKO.ICF 
CM_141 GGAAAACCACGTCCCCGTG 62 R Sequencing pKO.ICF 
CM_143 CGATCGCTGCCAGGATATAC 62 F Sequencing pKO.ICF 
CM_144 GTATATCCTGGCAGCGATCG 62 R Sequencing pKO.ICF 
CM_145 CCGTAACCTGGATAGTGAAAC 62 F Sequencing pKO.ICF 
CM_146 GTTTCACTATCCAGGTTACGG 62 R Sequencing pKO.ICF 
CM_147 TTCTGGGCTCAGAGGCTGG 62 F Sequencing pKO.ICF 
CM_148 CCAGCCTCTGAGCCCAGAA 62 R Sequencing pKO.ICF 
CM_149 GCTCCTGCCGAGAAAGTATC 62 F Sequencing pKO.ICF 
CM_150 GATACTTTCTCGGCAGGAGC 62 R Sequencing pKO.ICF 
CM_151 GCTCGCTGATCAGCCTCGA 62 F Sequencing pKO.ICF 
CM_152 TCGAGGCTGATCAGCGAGC 62 R Sequencing pKO.ICF 
Table 2-2 Oligodeoxyribonucleotides for the generation of Trpc1-flox targeting vector and 










CM_159 GCTCCATTGTTACTTCACATG 60 F Cloning of 5’Probe1Trpc1_C1Z 
CM_160 CCTGCTGTATGTTCTGATCAG 62 R Cloning of 5’Probe1Trpc1_C1Z 
CM_161 CCAGTGTCCAAGTACCACAAC 64 F Cloning of 5’Probe2Trpc1_C1Z 
CM_162 CCTGCGCTATCTGAAATTTCAG 64 R Cloning of 5’Probe2Trpc1_C1Z 




CM_163 GGCTAAACATTTTGCTGAGCA 60 F Cloning of 5’Probe3Trpc1_C1Z 
CM_164 CCTCGTTCCTAAAGGCGTTT 60 R Cloning of 5’Probe3Trpc1_C1Z 
CM_165 CCTTGGATGAAGGACCAAGTT 62 F Cloning of 3’Probe1Trpc1_C1Z 
CM_166 CCAGTATAGCAAAATCAGTGTC 62 R Cloning of 3’Probe1Trpc1_C1Z 
CM_167 CCAAGTCAGTGTGCTTAGGC 62 F Cloning of 3’Probe2Trpc1_C1Z  
CM_168 CCAAGAATGAAACTACAGCAGA 62 R Cloning of 3’Probe2Trpc1_C1Z 
AR_1 CCTGCCCTAGTTGCCGAAA 60 F Sequencing 5’Hom Trpc1_C1Z 
AR_2 TTTCGGCAACTAGGGCAGG 60 R Sequencing 5’Hom Trpc1_C1Z 
AR_3 GGTTTAAGTCAACAACATCTCC 62 F Sequencing 5’Hom Trpc1_C1Z 
AR_4 GGAGATGTTGTTGACTTAAACC 62 R Sequencing 5’Hom Trpc1_C1Z 
AR_5 GGGTGAAGAGAGTATAATTAGT 60 F Sequencing 5’Hom Trpc1_C1Z 
AR_6 ACTAATTATACTCTCTTCACCC 60 R Sequencing 5’Hom Trpc1_C1Z 
AR_7 GGATTAAAGGCGTGCACCAC 62 F Sequencing 5’Hom Trpc1_C1Z 
AR_8 GTGGTGCACGCCTTTAATCC 62 R Sequencing 5’Hom Trpc1_C1Z 
AR_9 CCAGTAGGATTTCTTTGGGTT 60 F Sequencing 5’Hom Trpc1_C1Z 
AR_10 AACCCAAAGAAATCCTACTGG 60 R Sequencing 5’Hom Trpc1_C1Z 
AR_11 GCTAGCCCAGTTTCCAGTG 60 F Sequencing 5’Hom Trpc1_C1Z 
AR_12 CACTGGAAACTGGGCTAGC 60 R Sequencing 5’Hom Trpc1_C1Z 
AR_13 CCACTGTGAACTGAATCCAAC 62 F Sequencing 5’Hom Trpc1_C1Z 
AR_14 GTTGGATTCAGTTCACAGTGG 62 R Sequencing 5’Hom Trpc1_C1Z 
AR_15 GGGTTTGCTGTGTCACAGG 60 F Sequencing 5’Hom Trpc1_C1Z 
AR_16 CCTGTGACACAGCAAACCC 60 R Sequencing 5’Hom Trpc1_C1Z 
AR_17 CCAAAGACGAGATGTAACTTG 60 F Sequencing 5’Hom Trpc1_C1Z 
AR_18 CAAGTTACATCTCGTCTTTGG 60 R Sequencing 5’Hom Trpc1_C1Z 
AR_19 CGACTTAAGAGCATCACTTCA 60 F Sequencing 5’Hom Trpc1_C1Z 
AR_20 TGAAGTGATGCTCTTAAGTCG 60 R Sequencing 5’Hom Trpc1_C1Z 
AR_21 GGATGACAAGTTTGTGGCCT 60 F Sequencing 5’Hom Trpc1_C1Z 
AR_22 AGGCCACAAACTTGTCATCC 60 R Sequencing 5’Hom Trpc1_C1Z 
AR_23 GCGAGTGATCTAGAAGCGC 60 F Sequencing 3’Hom Trpc1_C1Z 
AR_24 GCGCTTCTAGATCACTCGC 60 R Sequencing 3’Hom Trpc1_C1Z 
AR_25 CCAGTCACTTAGCTGTCTAG 60 F Sequencing 3’Hom Trpc1_C1Z 
AR_26 CTAGACAGCTAAGTGACTGG 60 R Sequencing 3’Hom Trpc1_C1Z 
AR_27 CCACAGTCAGTCTATCAAGA 58 F Sequencing 3’Hom Trpc1_C1Z 
AR_28 TCTTGATAGACTGACTGTGG 58 R Sequencing 3’Hom Trpc1_C1Z 
AR_29 CCATACCTGACCCAAATGTC 60 F Sequencing 3’Hom Trpc1_C1Z 
AR_30 GACATTTGGGTCAGGTATGG 60 R Sequencing 3’Hom Trpc1_C1Z 
AR_31 CCAGGGAATCCAATGCCCC 62 F Sequencing 3’Hom Trpc1_C1Z 
AR_32 GGGGCATTGGATTCCCTGG 62 R Sequencing 3’Hom Trpc1_C1Z 
AR_33 CCTATAAGAGCAGTCACAGC 60 F Sequencing 3’Hom Trpc1_C1Z 
AR_34 GCTGTGACTGCTCTTATAGG 60 R Sequencing 3’Hom Trpc1_C1Z 
AR_51 CCGTCAGGATGGCCTTCTG 62 F Sequencing 5’Hom Trpc1_C1Z 
AR_52 GGGAGTTAAGGAGGGAGGGA 62 F Sequencing 5’Hom Trpc1_C1Z 
AR_53 CCGCCAGCCTGTATTTCGG 62 F Sequencing 5’Hom Trpc1_C1Z 
AR_54 CCGAAATACAGGCTGGCGG 62 R Sequencing 5’Hom Trpc1_C1Z 
AR_55 CTTGAGGCTGGACATGTGCC 64 R Sequencing Trpc1_C1Z 
AR_56 CCTCCAGCGCGGGGATCT 62 F Sequencing Trpc1_C1Z 
AR_57 AGATCCCCGCGCTGGAGG 62 R Sequencing Trpc1_C1Z 




AR_58 CTGTGCACATGTCCACATGC 62 R Sequencing Trpc1_C1Z 
AR_59 CCCTGCATCAGACGGAAGTAA 62 F Sequencing Trpc1_C1Z 
AR_60 TTACTTCCGTCTGATGCAGGG 62 R Sequencing Trpc1_C1Z 
AR_61 GGAGTTAGATCAGGAAGCGC 62 F Sequencing Trpc1_C1Z 
AR_62 GCGCTTCCTGATCTAACTCC 62 R Sequencing Trpc1_C1Z 
AR_63 CTAGACAGCTAAGTGACTGG 60 R Sequencing 3’Hom Trpc1_C1Z 
AR_64 GTACAGCGGTACAGAAGACC 62 R Sequencing 3’Hom Trpc1_C1Z 
AR_65 GATTGGGAAGACAATAGCAGG 62 R Sequencing Trpc1_C1Z 
AR_66 CAGCTTACGAACCGAACAGG 62 R Sequencing Trpc1_C1Z 
AR_67 CCTTTGGCTTTCACACCACC 62 R Sequencing 3’Hom Trpc1_C1Z 
AR_68 CCTTGAAGGACTCCAATAGG 60 R Sequencing Trpc1_C1Z 
AR_69 CCAGAGGCTCAAGGCTGAGT 64 F Sequencing Trpc1_C1Z 
AR_70 ACTCAGCCTTGAGCCTCTGG 64 R Sequencing Trpc1_C1Z 
AR_71 CCATTCGACCACCAAGCGAA 62 F Sequencing Trpc1_C1Z 
AR_72 CCTGCATCAGACGGAAGTAAA 62 F Trpc1_C1Z _loxP-PCR  
AR_73 GTGAGGAACATTTATTCATGTG 60 R Trpc1_C1Z _loxP-PCR  
AR_74 CCTGTTTCCTTTCCCTGCAT 60 F Trpc1_C1Z _loxP-PCR  
AR_75 AGGAGAAAACCAAATTGAACTG 60 R Trpc1_C1Z _loxP-PCR  










AR_76 GGATTTGCTTGGCTTTCGGA 60 F Trpc1_SubF_IC_genotyping  
AR_77 CAAAAGACGGCAATATGGTGG 62 R Trpc1_SubF_IC_genotyping  
AR_78 CTTCGGCCAGTAACGTTAGG 62 R Trpc1_SubF_IC_genotyping  
AR_79 GGGCGGAATTCATCGATGAT 60 R Trpc1_SubF_IC_genotyping  










AR_80 CCGCCAGCCTGTATTTCGG 62 F Trpc1_MANN_flox_genotyping  
AR_81 GCGGAATTCTCTAGAGTCCA 60 R Trpc1_MANN_flox_genotyping  
AR_82 CCGGTCGCTACCATTACCA 60 F Trpc1_MANN_flox_genotyping  
AR_83 GCGTGCAATCCATCTTGTTC 60 R Trpc1_MANN_flox_genotyping  
AR_84 CCTTCTTGACGAGTTCTTCTG 60 F Trpc1_MANN_flox_genotyping  
AR_85 GCTGGGTCTAGATATCTCGA 60 R Trpc1_MANN_flox_genotyping  
AR_86 GGACTACGGTTGTCAGGTAC 62 F Trpc1_MANN_flox_genotyping  










SD_222 CCCATTCCATGCGGGGTATCG 68 F Flp recombinase_genotyping 
SD_223 GCATCTGGGAGATCACTGAG 62 R Flp recombinase_genotyping 
Cre_1 ACCTGAAGATGTTCGCGATTATCT 68 F Cre recombinase_genotyping 
Cre_2 ACCGTCAGTACGTGAGATATCTT 64 R Cre recombinase_genotyping 












72 R GFP_genotyping 
 
2.2.1.4  List of buffer solutions  
For miniprep (crude preparation of small 
amount of plasmid DNA) 
STET-L buffer, pH 8.0  
8% (w/v)   Sucrose 
5% (v/v)    Triton X-100 
0.05 M      EDTA 
0.05 M      Tris 
Add Lysozyme (100 μg/mL) freshly added 
from 10 mg/mL Lysozyme stock solution 
For maxiprep (preparation of large amount, 
≥0.5 mg, of plasmid DNA) 
Cell resuspension solution 
50 mM Tris-HCl (pH 7.5)  
10 mM EDTA  
100 µg/mL RNase A 
 
Cell lysis solution 
0.2 M      NaOH 
1% (w/v) SDS 
 
Neutralization solution, pH 4.2 
4.09 M guanidine hydrochloride 
0.759 M potassium acetate   
2.12 M glacial acetic acid 
For DNA storage TE-buffer, pH 8.0, autoclaved 
10 mM  Tris       
  1 mM  EDTA    
For preparation of chemical competent 
bacterial cells 
Transformation storage solution (TSS) buffer 
10% (w/v)  PEG 3350 
5% (v/v)     DMSO 
1% (w/v)    Tryptone/Peptone  
1% (w/v)    NaCl 
0.5% (w/v) Yeast extract 
0.05 M        MgCl2 
For gel electrophoresis Tris-Borate-EDTA (TBE) buffer, pH 8.0 
90 mM    Tris base 
90 mM    Boric acid 
  2 mM    EDTA  
Loading buffer (6x) 
0.25% (v/v)  Bromophenol blue  
15% (w/v)    Ficoll 400 
0.25%  (v/v) Xylencyanol  




For genotyping PCR 10x Taq buffer, pH 8.3 
0.1 M       Tris 
0.5 M       KCl 
0.015 M   MgCl2 
For genomic DNA preparation for 
genotyping 
Tissue lysis buffer, pH 8.0 
50   mM   Tris HCl 
100 mM   NaCl 
    1  mM   EDTA 
0.5%  (w/v)  proteinase K 
0.2%  (w/v)  Nonidet P40 
0.2%  (w/v)  Tween-20 
For Southern blot 0.25 N Hydrochloric acid 
20.76 mL Hydrochloric acid (37%) ad 1000 
mL deionized H2O; used for depurination 
Denaturation buffer 
0.5 M NaOH 
1.5 M NaCl 
Neutralization buffer, pH 7.5 
0.5 M Tris       
   3 M NaCl 
10x SSC, pH 7.0 
0.15 M  Sodium citrate 
1.5   M  NaCl 
Church buffer 
0.5 M         Sodium phosphate (pH 7.4)  
1% (w/v)    BSA 
7% (w/v)    SDS 
1 mM         EDTA 
0.1 mg/mL Salmon sperm DNA, Roche, 
(added after being denatured at 95°C for 5 
minutes) 
 
2.2.1.5   Media for bacterial culture 
Luria-Bertani (LB) medium, pH 7.4 
Tryptone/Peptone   10 g 
NaCl                            10 g 
Yeast extract               5 g 
Deionized H2O           ad 1000 mL 
autoclaved at 121°C, 2.0 bar for 20 minutes. 
 
LB-agar 
15 g/L agar in LB-medium, autoclaved at 121°C, 2.0 bar for 20 min and plated after cooling 
down to 50°C. 
 





Added in LB-medium just before plating at the following final concentrations  
Ampicillin 50 μg/mL 
Kanamycin 25 μg/mL   
2.2.2 General methods 
2.2.2.1  Restriction endonuclease treatment of plasmid DNA 
Restriction enzyme reactions were carried out to generate the required DNA fragments for 
linearization of vector plasmids and validation of the integrity of the recombinant plasmid. 
Single or combinations of two different restriction enzymes were used in the reactions. 
Combinations of enzymes were used either simultaneously if reaction conditions were similar 
for both enzymes or a sequential incubation approach was used if reaction conditions were 
different for each enzyme. Table below summarizes the composition of a typical restriction 
digest used: 
Component (reagent) Quantity (µL) Final concentration 
Template DNA variable 0.5-2 µg 
Enzyme 1 1 10 U* 
Enzyme 2 1               10 U 
Restriction buffer (10x) 5                  1x 
Water, nuclease-free ad 50 µL  
                     *usually ≤1/10 of total volume 
After pipetting, all components were thoroughly mixed and incubated at 37°C or 25°C 
depending on the enzyme. 
2.2.2.2  Gel electrophoresis 
Agarose gel electrophoresis was used for the separation of DNA fragments based on their 
sizes. 0.6-4% agarose gels were used depending on the expected band sizes in the individual 
cloning steps. The agarose gel was prepared by dissolving agarose standard (CarlRoth) powder 
in 1xTBE-buffer and boiled for several minutes in a microwave until a transparent solution was 
obtained. Approximately, after 3 min of mild cooling by keeping at 21°C, ethidium bromide 
(0.05% v/v) was added followed by pouring the agarose solution into a gel tray. Ethidium 
bromide, a fluorescent dye, intercalates with the DNA double strands and absorbs radiation 
at wavelengths from 302 nm to 366 nm and re-emits energy at 590 nm (Le Pecq and Paoletti, 
1966). The agarose gel solution was incubated for 20 min at 21°C for solidification and finally 




stored at 4°C or directly used for running the samples. The DNA samples were solved in loading 
buffer (10x) applied to the gel wells and electrophoresis was performed at 100–150 V (Consort 
EV 261). Molecular weight markers were run in the same gel to determine the molecular 
weights of DNA products. The separated DNA fragments were visualized using a UV light 
transilluminator (HeroLab UVT-28 ME-HC) and images were taken using an attached camera 
(Herolab B1228-U5). For the gel purification of DNA fragments, an appropriate DNA band was 
excised from the gel using a sterile scalpel, the DNA was extracted from the gel by either 
electroelution or using a Wizard SV gel and PCR clean up system (Promega) according to the 
manufacturer’s instructions.  
2.2.2.3  Purification of DNA by electroelution 
The excised portion of an agarose gel containing the required DNA fragment was placed inside 
a dialysis bag (Dialysis Tubing, Sigma-Aldrich) and 250 µL of autoclaved 1xTBE buffer was 
added (avoiding air bubbles as much as possible). The dialysis bag was sealed with the plastic 
clips and placed in a special electrophoresis chamber (Bio-Rad, PowerPac HC) for 
electroelution to occur at 135 mA at 4°C for 20-30 minutes. Electroelution was briefly 
monitored by UV light (312 nm). When electroelution was complete the solution containing 
the eluted DNA was collected. The bag was rinsed with additional 250 µL nuclease free H2O 
and added to the solution containing the DNA. The DNA was finally purified using the high 
pure PCR product purification kit (Roche) which works on the principle of binding of DNA to 
the special glass fibers of filter tubes due to the presence of chaotropic salt guanidine 
thiocyanate and subsequent washing steps to remove the contaminants. The DNA 
concentration was determined using a NanoDrop spectrophotometer. The DNA was stored at 
-20°C until used for the ligation reaction.  
2.2.2.4 Dephosphorylation of a plasmid DNA 
Antarctic phosphatase was used to dephosphorylate 5’ and 3’ ends of DNA to prevent re-
ligation of a linearized plasmid. The following protocol was applied: 
26 μL    linearized plasmid DNA  
  3 μL    10x antarctic buffer 
  1 μL    antarctic phosphatase (5U/µL) 




The reaction mixture (30 µL) was incubated at 37°C for 60 min; afterwards the enzyme was 
inactivated by incubating the sample at 80°C for two minutes. The dephosphorylated plasmid 
DNA was stored at -20°C until used for ligation reaction.  
2.2.2.5  Generation of recombinant plasmids by a ligation reaction 
The T4 DNA ligase catalyzes the formation of a phosphodiester bond between juxtaposed 5’- 
phosphate and 3’-hydroxyl ends in double stranded DNA. In a ligation reaction, ratio of mol 
vector and mol fragment ranges from 1:3 to 1:10. The protocol was as follows: 
variable      plasmid DNA (vector) 
variable      fragment DNA (insert)     
  1 μL          T4 DNA Ligase (400U/ µL) 
  2 μL          10x ligase buffer 
20 µL          ad deionized water  
The reaction mixture was incubated at 21°C for 60 min for ligation of “sticky” ends or overnight 
at 16°C for ligation of “blunt” ends. The ligase enzyme was inactivated at 65°C for ten minutes. 
The recombinant plasmids were then used to transform bacteria.  
2.2.2.6  Bacterial transformation  
Transformation refers to the process of direct up-take of exogenous plasmid DNA by bacteria 
through the membrane on exposure either to a chemical or electrical stimulus. Bacteria which 
have the ability of accepting foreign DNA are called the competent cells. 
Generation of competent bacteria 
To generate competent bacteria, E.Coli were grown overnight on ampicillin containing LB agar 
plates. One colony was used to inoculate 5 mL LB medium and thereafter the suspension was 
incubated for 16 h at 37°C without any antibiotic to obtain a pre-culture. Under sterile 
conditions, 1 mL pre-culture was added to 100 mL LB medium present in a baffled-flask and 
incubated for 2 h at 37°C with gentle shaking (orbital) at 260 rpm. Once the optical density 
(OD600) reached 0.4-0.5, the bacterial suspension was centrifuged at 1600 g for 10 min at 4°C. 
The supernatants were discarded and the pellet was re-suspended in 15 mL ice-cold 
transformation storage solution (TSS) (Chung et al., 1989). A total amount of 300 µL 
suspension was added to pre-cooled 1.5 mL eppendorf tubes followed by snap freezing using 
liquid nitrogen. The competency of prepared chemically competent bacterial cells was 
estimated by transforming the plasmid pUC18 and plating the transformed bacteria on 




ampicillin containing plates. The transformation efficiency should be 5x106 to 5x107 
independent bacterial colonies per µg pUC18 DNA. The bacterial cells were stored at -80°C 
until used for the transformation of ligation products during individual cloning steps.  
Transformation of chemically competent bacterial cells 
The suspension containing competent bacteria (300 µL) was thawed at 4°C for 5 min followed 
by the addition of 20 µL plasmid/ligation reaction and incubated for 30 min at 4°C. After 
incubation for 2 min at 42°C (water-bath) the suspension was immediately incubated for 2 
min at 4°C. Pre-warmed 900 µL LB-medium was added to the bacterial suspension, followed 
by incubation for 1 h at 37°C with mild shaking (150 rpm). A portion of bacterial suspension 
(150 µL) was transferred onto a specific antibiotic-resistant LB-agar plate and the remaining 
portion was centrifuged at 800 g for 2 minutes.  The supernatants were discarded and the 
pellet was dissolved in 150 µL LB medium and finally plated on a second LB-agar plate. The 
plates were incubated for approximately 16 h (overnight) at 37°C. The resulting bacterial 
colonies were used for the isolation of plasmid DNA.  
2.2.2.7  Extraction of plasmid DNA 
The isolation of plasmid DNA from bacteria is divided into two procedures based on the 
amount of DNA to be isolated. 
Analytical isolation of plasmid DNA (Miniprep) 
The "boiling method" (Holmes and Quigley, 1981) was used with slight modifications for the 
isolation of plasmid DNA. Individual bacterial colonies were picked by autoclaved wooden 
toothpicks under sterile conditions and used to inoculate 5 mL LB medium containing 
ampicillin. The tubes were incubated overnight at 37°C with mild shaking in an orbital shaker 
at 270 rpm. A portion of bacterial suspension was poured into 1.5 mL eppendorf tubes and 
centrifuged at 16100 g for 1 minute. The supernatants were discarded and the pellet was 
dissolved in 300 µL freshly prepared STET-L buffer. The tubes were incubated for 5 min on ice 
followed by a thermal shock for 1 min at 95°C. After centrifugation at 16100 g for 15 min, a 
gelatinous pellet was obtained. The pellet was removed with the wooden toothpick under 
sterile conditions and 300 µL of isopropanol was added followed by centrifugation at 16100 g 
for 30 minutes. The supernatants were discarded and the precipitate was washed (16100 g x 
10 min) with 500 µL of 70% (v/v) ethanol, air-dried and dissolved in 50 µL water with RNase 
(40 µg/mL). The DNA was subjected to endonuclease restriction enzyme digestion. 




Preparative isolation of plasmid DNA (Maxiprep) 
After identifying the bacterial clones carrying the desired plasmid DNA by restriction enzyme 
digestion and subsequent sequencing, the next step was to isolate the plasmid DNA on a larger 
preparative scale. An Erlenmeyer flask containing 250 mL LB-medium and appropriate 
antibiotic was inoculated with 500 µL of bacterial suspension containing the desired plasmid. 
The flask was incubated overnight at 37°C with mild shaking at 200 rpm in an orbital shaker. 
For DNA isolation, two different maxiprep kits were used: Promega PureYield plasmid 
maxiprep System (Promega) and Qiagen plasmid Plus maxi kit (Qiagen). The extraction of 
plasmid DNA is based on the principle of alkaline lysis of bacterial cells followed by removal of 
the contaminants and binding of DNA to a column, finally plasmid DNA is eluted from the 
column in an appropriate buffer solution after successive washing steps. The DNA was 
extracted according to the manufacturer’s instructions and stored at -20°C until use for other 
cloning purposes. The amount and integrity of the isolated DNA was analyzed using a 
NanoDrop spectrophotometer.  
2.2.2.8  Determination of DNA concentration and quality 
The concentration and quality of a DNA sample in an aqueous solution was determined by 
measuring its UV absorbance at 260 and 280 nm. The NanoDrop 1000 spectrophotometer 
(Thermo Scientific) was used which measures samples as small as one µL with high accuracy 
and reproducibility. The purity of the DNA was estimated by comparing the ratio of 
absorbance at 260 and 280 nm.  A ratio of ˃1.8 was considered to be a pure DNA sample. The 
base line of the NanoDrop 1000 was set by water or TE buffer.  
2.2.3 Southern blot technique 
Southern blotting involves the transfer of electrophoretically separated DNA fragments onto 
a filter membrane and subsequent fragment detection by hybridizing with a radioactively 
labelled DNA probe. For Southern blot, 15-30 µL of hydrolyzed genomic DNA was incubated 
overnight at 37°C by a specific endonuclease restriction enzyme (40 U); the fragments were 
electrophoretically separated on a 0.6% agarose gel along with a marker, a 1 Kb DNA ladder 
(Invitrogen). Electrophoresis was performed at 140 V for about 3.5-4 h followed by imaging of 
the gel under UV light (HeroLab UVT-28 ME-HC). A fluorescent ruler was coincided with the 
gel in such a way that the starting zero-point matched to the level of loading wells for 




estimation of DNA sizes after hybridization. After imaging, the gel was treated with 0.25 N HCl 
for 45 min for the depurination of genomic DNA. Depurination lays the phosphate-sugar 
backbone of DNA open to subsequent cleavage by hydroxyl ions. By this procedure the DNA 
is nicked, which improves transfer of fragments ˃10 Kb. Subsequently the gel was rinsed with 
distilled water, followed by incubation with the denaturation and neutralization buffers for 45 
and 30 min respectively, with mild shaking at 21°C. Denaturation ultimately causes the 
conversion of a double-stranded DNA structure into a single strand DNA molecules by 
breaking the hydrogen bonds present between the complementary strands of the double helix 
of DNA. The gel was washed once with distilled water and placed over a Whatman 3MM filter 
paper lying on two spontex sponges soaked in 10x SSC transfer buffer in a steel pan. A gel-
sized pre-wet Hybond-N nylon membrane (RPN203N, GE Healthcare, Amersham) was placed 
over the gel squeezing out the air bubbles by rolling a glass pipette, followed by two or three 
Whatman filter papers, a stack of tissue papers and a metal or glass plate. A weight of about 
0.8-1 kg was placed on the top of the plate to start the transfer of genomic DNA towards the 
membrane by a capillary action. In order to prevent any leaky transfer of the buffer, the empty 
space around the gel was covered with parafilm strips. After 16 h of incubation, the nylon 
membrane was removed and transferred DNA was immobilized by cross-linking in Stratalinker 
UV cross linker (Agilent) at 0.12 J/cm2, autocrosslink mode, followed by incubating the 
membrane at 80°C for two hours. 
2.2.3.1  Southern probes preparation and labeling 
The Southern probes (5’ and 3’ probes) for both targeting constructs, pAR_11 and C1Z, used 
for the generation of Trpc1-IC knock-in and conditional Trpc1 knockout mice respectively, 
were prepared by the PCR amplification of genomic DNA, obtained from mouse (mus 
musculus, C57BL/6N strain) DNA using different primer combinations (Table 2-1, 2-2). These 
primer combinations (forward and reverse) were designed to amplify specific regions called 
probes, ranging from 450 bp to 780 bp in length, placed outside the homology arms to detect 
the precise integration of a targeting construct within the endogenous DNA in ES cells upon 
homologous recombination. The PCR reaction mix and conditions used for the generation of 
5’ and 3’ probes are shown below:  
 





Component (reagent) Quantity (µL) Final concentration 
Genomic DNA 1 variable 
5x Phusion buffer HF 10 1x 
10 mM dNTP’s 1 200 µM 
2U/µL DNA polymerase 0.5 1 U 
10 µM forward primer 2.5 0.5 µM 
10 µM reverse primer 2.5 0.5 µM 
Deionized H2O ad 50  
PCR protocol: 
Steps Temperature (°C) Time  Number of cycles 












       Final extension 72 5 min 1 
Hold 4 α  
The amplified PCR product was subcloned into the EcoRV cut pUC18 or pBlueKS cloning 
vectors. After ligation and transformation, the bacterial clones containing a desired 
recombinant plasmid were selected after miniprep, restriction enzyme cut and sequencing. 
The correct plasmids were prepared by maxiprep and the amplified DNA fragments obtained 
by appropriate restriction enzymes. In the next step the cDNA fragments were labelled by 32P. 
A random oligo-primed DNA synthesis method was used to label DNA fragments to be used 
as probes for Southern hybridization. The probe labeling was performed using a Megaprime 
DNA labeling system (GE Healthcare Life Sciences). The reaction mixture was composed of 
DNA (≈25-30 ng), denatured by incubating at 95°C for 10 min and subsequent chilling for 3 
min at 4°C, an appropriate amount of random hexamer primers, reaction buffer, Klenow 
polymerase and a mixture of nucleotides including 32PdCTP (Hartman Analytic). 
Component  Quantity (µL) 
DNA (≈25-30 ng) variable 
Primer solution 5 




32PdCTP (10 µCi/µL) 5 
Klenow’s enzyme (1 U/µL) 2 




Deionized H2O ad 50 
The mixture was incubated for 30 min at 37°C. The polymerase incorporated the nucleotides 
including the radioactive 32PdCTP into the newly synthesized complementary DNA 
(Feinberg and Vogelstein, 1984). The DNA was separated from non-incorporated nucleotides 
with 1x TE-buffer by gel filtration through NICK-columns Sephadex G-50 DNA grade (Cat. No. 
17-0855-02, GE Healthcare). The elutes from the columns were collected in six individual 
tubes. To identify the labelled DNA and to quantify the efficacy of 32PdCTP incorporation, 
the aliquots from the six tubes were measured by liquid scintillation counting in a Wallac 1409 
scintillation counter. The fractions 2 and 3 contained the labelled probes, which were later 
used for the hybridization.  
2.2.3.2  Southern hybridization 
Southern blot membrane was pre-hybridized by incubating for two hours at 65°C (mild 
shaking) in pre-warmed Church buffer (Church and Gilbert, 1984) to block the non-specific 
binding sites of the membrane. After pre-hybridization, the membrane was incubated with 
the hybridization solution (1 mL/cm2 membrane surface) overnight at 65°C in a sealed plastic 
bag. The hybridization solution consisted of church buffer and denatured 32PdCTP labelled 
probe (2-4x107 cpm/mL). The denaturation of probe was carried out at 95°C for 10 min 
followed by rapid chilling at 4°C for 3 minutes. After overnight hybridization, the membrane 
was washed twice with increasing stringency i.e. 2x SSC/1% SDS followed by 0.4x SSC/1% SDS 
in a shaking water bath at 65°C for 15 min each. After the first washing step, the radioactivity 
on the blot and in the washing solution was monitored by a Geiger-Müller counter (LB 122, 
Berthold). The membrane was then exposed to a phosphoimager screen (Fujifilm BAS-IP MP 
2040) which was scanned after 4 h and 24 h of exposure time by a phosphoimager (BAS reader, 
Raytest). In cases of weaker signals obtained after 24 h exposition time, the membrane was 
exposed for additional three days to one week.  
2.2.4  ES cell gene targeting 
The strategy and generation of the targeting constructs is described in the “Results” section. 
The vectors carrying the final targeting constructs (100 µg) were linearized by incubation in 
the presence of restriction endonucleases at 37°C for 4-7 hours. The linearized plasmids were 
cleaned by High pure PCR product purification kit (Roche) and send on ice to ingenious 
Targeting Laboratory, iTL, (Ronkonkoma, New York, USA). iTL performed electroporation into 




C57BL/6 ES cells and selected ES cell clones by positive and negative selection. Aliquots of 
selected ES cells were sent to Homburg and I prepared DNA from these clones performed 
Southern blot analysis using 3’-, 5’- and neo DNA probes.   
2.2.5  Detection of positively targeted ES cell clones 
After electroporation, ES cell clones were picked up by iTL and 288 lyophilized clones were 
shipped in nine 32-well plates. The DNA of these clones was dissolved by the addition of 300 
µL 1xTE buffer followed by incubation at 55°C for 3 h with mild shaking (300 rpm). The genomic 
DNA was stored at 4°C until restriction enzyme cut, agarose gel electrophoresis and Southern 
blot analyses were performed. For the detection of correctly targeted ES cell clones three 
probes were used; a 5’- probe and 3’- probe also known as “external probes” derived from 
sequences outside the homology arms and the neomycin resistance (neo) probe also known 
as “internal probe”. The targeting construct, C1Z contained one of the loxP sites present 
adjacent to the 3’ homology arm, therefore additional PCR was performed to confirm the 
correct insertion of that particular loxP site upon homologous recombination. According to 
the results of Southern blot and PCR the correct ES cell clones (5-6 in both cases) were 
expanded and karyotyped by iTL. The selected clones were then injected into the BALB/c 
blastocysts by iTL and by Interfakultäre Biomedizinische Forschungseinrichtung (IBF) 
Heidelberg University. Blastocysts were then transferred in pseudopregnant mothers which 
gave birth to pups which carried or did not carry the targeted allele.  
2.2.6 Genotyping strategy for the identification of germline transmission of 
the inserted mutation 
A PCR based genotyping strategy was established to distinguish between wild-type and 
mutant mouse strains in the F1 generation. Several primer combinations were designed 
spanning over various regions of the mutant allele. After identification of the desired mutant 
mouse strain, the mice were transferred to our laboratory from iTL. The heterozygous mice 
were housed in the quarantine of the animal facility of the Medical Faculty directed by Dr. 
Petra Weissgerber (Gebäude 61.4, Uniklinikum Homburg). By embryo transfer mice were 
introduced into the specific pathogen free animal facility. Mice were kept under a standard 
light/dark cycle (12 h) with food and water ad libitum. All breeding were conducted according 
to the regulations of the local authority and the ethics committee of the Saarland.  




2.2.6.1  Genomic DNA preparation  
Genomic DNA required for genotyping PCR was isolated from tissue samples obtained from 
individual mice by an ear punch. The tissue sample was incubated in lysis buffer for 
approximately 16 h at 55°C with vigorous shaking and stored thereafter at 4°C until use. One 
µL of the lysed tissue was taken as a template to perform PCR to identify the genotype. 
2.2.6.2  Genotyping PCR  
The PCR protocol and steps used were: 









b. PCR steps: 
 
Gene PCR conditions Fragment size (bp) 
Flp 94°C : 3 min 
94°C : 30 s  
58°C : 60 s               35x 
72°C : 60 s 
72°C : 5 min 
15°C: ∞  
mt fragment: 750 
Trpc1-IC KI 
and Cre-recombinase 
94°C : 90 s 
94°C : 30 s  
65°C : 30 s               10x*  
72°C : 30 s 
94°C : 30 s      
60°C : 30 s               26x  
72°C : 30 s   
Trpc1-IC KI detection: 




mt fragment: 392 




Genomic DNA 1 variable 
10x PCR buffer 2.5 1x 
10 mM dNTPs 0.5 200 µM 
25 mM MgCl2 0.5 500 µM 
Taq polymerase 1 ≈1 U 
10 µM forward primer 1.25 0.5 µM 
10 µM reverse primer 1.25 0.5 µM 
Deionized H2O ad 25  




72°C : 5 min   
15°C : ∞ 
eROSA26 94°C : 5 min 
94°C : 35 s  
56°C : 45 s                35x 
72°C : 90 s 
72°C : 7 min 
15°C : ∞ 
wt fragment: 256 




*(0.5°C decrease per cycle)     
 
2.2.7 Statistical methods 
Data were analyzed using Microsoft Excel and GraphPad Prism 5. Data are shown as mean ± 
SD or mean ± SEM. To estimate the significance of differences, two-tailed unpaired student’s 
t-test for two groups and one way ANOVA followed by Bonferroni multiple comparison test 
for more than two groups were performed. The difference was found significant if the P-value 






In this section, the results obtained for the three major goals of my thesis have been described.  
3.1 Micro-computed tomography 
3.1.1 Bone microarchitecture of different strains of wild-type mice  
In order to understand the bone microarchitecture and to dissect the roles of TRP channels- 
especially of TRPC1 and TRPV6 in bone, I had to establish µCT of long bones as a method to 
screen bone microarchitecture. An important point is that bone microarchitecture changes 
with age and strongly depends on the mouse strain. So before comparing bones from wild-
type mice with the bones from Trpc1-/-, Trpv6mt/mt and Trpc1-/-/Trpv6mt/mt mice, a clear 
phenotypic characterization of the bones from wild-type mice of the most common strains 
used for gene targeting, B6 strain (C57BL/6) and mice of a mixed genetic background 
(129SvJ/C57BL/6) had to be analyzed. 
For that purpose, I had first to establish the use of a SkyScan1172 µCT and data acquisition 
using appropriate tasklists of the available software. With good advice from Dr. Phil Salmon, 
Application Scientist at Bruker microCT Systems, Kontich, Belgium, and with great help from 
Professor Dr. Bram van der Eerden from Erasmus Medical Centre, Rotterdam, The 
Netherlands, I succeeded in establishing the µCT methods of analyses. We decided to analyze 
only long bones, femurs, from male mice to reduce additional effects of the cycling hormonal 
status on bones, which is most prominent in females. 
First, I weighed the C57BL/6 (from now on “B6”) and the 129SvJ/C57BL/6 (from now on 
“mixed”) mice at different ages (Figure 3-1A, B) and determined the femur length (Figure 3-
1D, E). Until 20-week of age there was a steady increase in weight of mice of both strains, with 
mixed mice were approximately 10% heavier especially at week 2 and week 12 compared to 
C57BL/6 (Figure 3-1C). The length of femurs from mixed mice reached maximum (16.5 ± 0.24 
mm) at week 12 (Figure 3-1D) but femur length from C57BL/6 increased from week 2 (8.4 ± 
0.67 mm) to week 24 (15.99 ± 0.22 mm) (Figure 3-1E). Femur length of mixed mice was slightly 






Figure 3-1 Comparison of weight and femur length of wild-type mice on mixed 
(129SvJ/C57BL/6) and B6 (C57BL/6) strains of different age groups. (A, B) Comparison of 
weight and (D, E) femur length estimated by µCT of wild-type male mice on mixed genetic 
background 129SvJ/C57BL/6 (grey bars) and B6 strain, C57BL/6 background (black bars) of 
different ages such as 2, 9, 12, 20 and 24 weeks. For the estimation of differences between 
the strains, ratios were calculated for weight (C) and femur length (F). Data shown as mean ± 
SD with n, number of mice or femurs given below the bar graphs. Data analysed by one-way 
ANOVA with consecutive Bonferroni multiple comparison test (p<0.05 *, p<0.001 ***). Age in 
weeks and n indicated below the bar graphs.  
Next, I analyzed the cortical parameters of femurs by µCT, averaged from fifty 6.5 µm cross-
sections from the middle of the femur’s diaphysis (Figure 2-5). Cortical bone parameters 
(Figure 3-2A) include bone volume, endocortical volume, cross-sectional thickness and 
perimeter. These parameters are highlighted in red in the left column of Figure 3-2A. In the 
right column the values obtained for femurs from C57BL/6 (B6) and 129SvJ/C57BL/6 mice 
(mixed) are indicated, for 12-week of age (black bars) and 24-week of age (grey bars). 
Endocortical volume and perimeters were increased in femurs from 24-week compared to 12-





(Figure 3-2A). In femurs from mice of the mixed background, bone volume and cross-sectional 
thickness decreased with age, whereas endocortical volume and perimeters were not 
changed. The estimated mineral density (g/cm3) of cortical bone was not significantly different 
between any of the groups tested (1.33 ± 0.02 (B6, 12-week), 1.32 ± 0.06 (B6, 24-week), 1.32 
± 0.01 (mixed, 12-week), 1.31 ± 0.05 (mixed, 24-week), number of femurs as in Figure 3-2). 
Table 3-1 summarizes all data obtained to characterize cortical bone by µCT. 
Trabecular bone parameters (Figure 3-2B) averaged from metaphyseal sections as shown in 
(Figure 2-5) include bone volume as percentage of total tissue volume, trabecular number, 
trabecular thickness and trabecular separation as highlighted in red in the left column (Figure 
3-2B). In addition, I determined the trabecular pattern factor, which describes the 3D 
connectivity of the trabeculae by calculating an index of relative convexity or concavity of the 
total bone surface (Morphometric parameters measured by SkyScanTM CT-analyser software). 
In mice of mixed background, the percentage of bone volume from tissue volume and the 
trabecular number decreased indicating an age-dependent loss of bone (Figure 3-2B, right 
column). These values are mirrored by an increase of trabecular separation and of the 
trabecular pattern factor (Figure 3-2B, right column) as well as an age-dependent loss of 
mineral density (g/cm3) (0.20 ± 0.04 (B6, 12-week) 0.19 ± 0.03 (B6, 24-week), 0.29 ± 0.02 
(mixed, 12-week) 0.16 ± 0.02 (mixed, 24-week)). Determination of mineral density measured 
by µCT is only an estimation considering the attenuation of X-rays by the bone compared to 
the attenuation of X-rays by calcium hydroxyapatite “phantoms”. (So far, we did not apply 
quantitative backscattered electron imaging, qBEI, which is only available in very few 
laboratories, as a direct method to determine bone mineral density). Table 3-2 summarizes 






Figure 3-2 Comparison of bone microarchitecture from 12- and 24-week-old wild-type male 
mice on B6 strain, C57BL/6 and mixed strain, 129SvJ/C57BL/6. (A) Cortical bone parameters, 
left column indicate the cross-sectional images to depict the cortical parameters, right column 
depicts the graphical representation of cortical bone parameters: Bone volume (mm3), 
endocortical volume (mm3), cross-sectional thickness (mm) and perimeter (mm). (B) 
Trabecular bone parameters, left column indicates the cross-sectional images to depict the 
trabecular parameters, right column shows the graphical representation of trabecular 
parameters such as bone volume fraction (%), trabecular number (1/mm), trabecular 
thickness (mm), trabecular separation (mm) and trabecular pattern factor (1/mm). Values 
shown as mean ± SD, the number of femurs for each group is indicated in the upper most bars-
graphs. Two-tailed unpaired student’s t-test was performed on 12- and 24-week-old mice 
dataset for each genetic background (p-value summary, p<0.05 *, p<0.01 **). Black and grey 





Femurs of mice from C57BL/6 showed only minor age dependent differences (Figure 3-2B and 
Table 3-1, 3-2): we observed a non-significant tendency of age-dependent reduction of 
percentage of bone volume and trabecular number, which however was sufficient to yield a 
significant increase of trabecular separation. The trabecular pattern factor and the mineral 
density estimated by µCT were not different. 
 
Table 3-1 Comparison of cortical bone parameters of 12- and 24-week-old mice on C57BL/6 
(B6) and 129SvJ/C57BL/6 (mixed) genetic backgrounds, Ø= no change, ↑= increase compared 
to reference in the left column and ↓= decrease compared to reference in the left column, 
calculated as mean ± SD by one-way ANOVA followed by Bonferroni multiple comparison test 
(* indicates p-value < 0.05 and *** p-value < 0.001). For example, perimeter of femurs 
obtained from 24-week B6 mice is increased compared to femurs from 12-week B6 mice (black 
arrow); bone volume of femurs from 12-week mixed mice is larger than bone volume of 
femurs obtained from 12-week B6 mice (red arrow); bone volume of femurs from 24-week 
mixed is smaller than bone volume of femurs from 12-week mixed mice (black arrow). 
By directly comparing the parameters obtained from the femurs from C57BL/6 and from 
mixed mice, the data revealed that cortical bone values from mixed femurs, independent of 
age, are larger than those from C57BL/6 femurs. Whereas in trabecular bone, values obtained 
only from 12-week mixed femurs, not from 24-week mixed femurs, are more effected 
compared to 12-week and 24-week C57BL/6 femurs. Accordingly, age-dependent differences 






Table 3-2 Comparison of trabecular bone parameters of 12- and 24-week-old mice on C57BL/6 
(B6) and 129SvJ/C57BL/6 (mixed) genetic backgrounds, Ø= no change, ↑= increase compared 
to reference in the left column and ↓= decrease compared to reference in the left column, 
calculated as mean ± SD by one-way ANOVA followed by Bonferroni multiple comparison test 
(* indicates p-value < 0.05, ** p-value < 0.01 and *** p-value < 0.001). For example, trabecular 
separation in femurs obtained from 24-week B6 mice is increased compared to femurs from 
12-week B6 mice (black arrow); bone volume fraction in femurs from 12-week mixed mice is 
larger than bone volume fraction in femurs obtained from 12- week B6 mice (red arrow); bone 
volume fraction of femurs from 24-week mixed is smaller than bone volume fraction of femurs 
from 12-week mixed mice (black arrow).          
3.1.2 Comparison of normal femur microarchitecture of WT, Trpc1-/-, 
Trpv6mt/mt and double mutant Trpc1-/-/Trpv6mt/mt mice 
Next I wanted to analyze femurs from wild-type, Trpc1-/-, Trpv6mt/mt and Trpc1-/-/Trpv6mt/mt 
mice. Before starting these experiments, I confirmed that transcripts of Trpc1 and Trpv6 are 
present in RNA extracted from 1) osteoclasts differentiated and cultivated from bone marrow, 
2) crushed femur and 3) osteoblasts migrating out of bone slices and cultivated thereafter. 
Figure 3-3 shows that Trpc1 transcripts are present in osteoclast (Figure 3-3A), crushed femur 
(Figure 3-3A, B) and in osteoblast (Figure 3-3C). By similar experiments, I could amplify Trpv6 
transcripts in crushed femur (Figure 3-3D) and thereby confirm previous results described by 






Figure 3-3 Trpc1 and Trpv6 transcripts are present in mRNA extracted from bone cells or 
bone. Representative agarose gels: (A) Amplification of the full length TRPC1-encoding 
transcript (2879 bp) from mouse bone marrow derived in vitro cultured osteoclasts and 
crushed bone (femur). (B), (C) Trpc1 transcript (403 bp) in mRNA from crushed bone (femur) 
and mouse bone marrow derived in vitro cultured osteoblasts. (D) Trpv6 transcript (242 bp) in 
mRNA from crushed bone (femur). Messenger RNA from brain and placenta or no mRNA 
(water) used as positive and negative controls. Size marker for each gel (Kb or bp) are 
indicated.  
Trpc1 and Trpv6 encode proteins, which form tetrameric cation channels. However, no 
antagonists for these two channel types are available. In order to get hold of these Trpc1 and 
Trpv6 function in bone we analyzed and compared femurs from Trpc1-/- mice, Trpv6mt/mt mice 
and Trpc1-/-/Trpv6mt/mt double mutant mice: Functional deficits or additional functions of the 
bones from mutant mice compared to bones from wild-type mice should point to the 
functions of Trpc1 and Trpv6. All mice of four different groups were on the same genetic 
background i.e. mixed strain (129SvJ/C57BL/6) and 24-weeks old. The length of femurs from 
Trpv6mt/mt mice and from Trpc1-/-/Trpv6mt/mt mice was smaller than the length of femurs from 
the wild-type and Trpc1-/-mice (Figure 3-4A) but their estimated cortical mineral densities 
were not different (Figure 3-4B).   
There was a significant increase in cortical bone volume of Trpc1-/-/Trpv6mt/mt femurs whereas 
endocortical volume was reduced by approximately 30% in Trpv6mt/mt and Trpc1-/-/Trpv6mt/mt 
femurs compared to WT and Trpc1-/- femurs. The cortical cross-sectional thickness was 
significantly increased in both Trpv6mt/mt and Trpc1-/-/Trpv6mt/mt femurs compared to WT and 
Trpc1-/- femurs. Moreover, there was a significant increase in cross-sectional thickness of 
Trpc1-/-/Trpv6mt/mt femurs compared to Trpv6mt/mt femurs. The perimeter of the femoral shaft 
was significantly reduced in Trpv6mt/mt and Trpc1-/-/Trpv6mt/mt femurs compared to the bones 
from wild-type and Trpc1-/- mice. In summary, the data indicate a prominent cortical 
phenotype especially in femurs from Trpv6mt/mt mice, which also persists in the Trpc1-/-






Figure 3-4 Analyses of intact femurs. Femur length (A), cortical- (B) and trabecular- (C) femur 
bone parameters of wild-type, Trpc1-/-, Trpv6mt/mt and double mutant Trpc1-/-/Trpv6mt/mt mice 
determined by µCT. Data are shown as mean ± SD, analyzed by one-way ANOVA followed by 
Bonferroni multiple comparison test (* indicates p-value < 0.05, ** p-value < 0.01 and *** p-
value < 0.001). The four genotypes are indicated in black (wild-type, WT), green (Trpc1-/-), red 
(Trpv6mt/mt) and blue (Trpc1-/-/Trpv6mt/mt), with the number of femurs for each group is 
indicated in the bottom squares. 
The µCT data revealed a prominent trabecular phenotype in Trpc1-/- compared to WT mice 
(Figure 3-4C). The ratio of trabecular bone volume/tissue volume, the mineral density and the 
trabecular thickness were significantly reduced in femurs of Trpc1-/- mice compared to femurs 
from WT mice. In line with these observations, trabecular separation and trabecular pattern 
factor were significantly increased in femurs of Trpc1 deficient mice compared to WT femurs. 
I also analyzed femurs from 12-week-old wild-type and Trpc1-/- mice on B6 background and a 





phenotype is independent of the genetic background. We also observed significant differences 
in trabecular parameters of femurs from both Trpv6mt/mt and Trpc1-/-/Trpv6mt/mt mice in 
comparison to femurs from Trpc1-/- mice: Trabecular bone volume fraction, mineral density 
and trabecular number were significantly increased while trabecular separation and 
trabecular pattern factor were significantly reduced in Trpv6mt/mt and Trpc1-/-/Trpv6mt/mt 
femurs compared to Trpc1-/- mice. In summary, trabecular bone volume fraction and mineral 
density is effected by Trpc1 deletion but not by Trpv6 mutation, which in Trpc1-/-/Trpv6mt/mt 
femurs rescues the wild-type phenotype. Similarly, the increased trabecular number and 
reduced trabecular separation is caused by mutation of Trpv6 both in Trpv6mt/mt and Trpc1-/-
/Trpv6mt/mt femurs. These differences in healthy bone parameters led us to establish a fracture 
model in our laboratory for studying the fracture healing, especially the callus formation in 
femurs after a defined fracture.  
3.1.3 Fractured femur analyses of wild-type, Trpc1-/-, Trpv6mt/mt and double 
mutant Trpc1-/-/Trpv6mt/mt mice 
As outlined in section 2.1.3.5 and Figure 2-6, I established a protocol to derive callus 
parameters of fractured femurs from 24-week-old male mice, four weeks after fracture, of 
four different genotypes. The fracture healing of WT mice were compared with the healing of 
Trpc1-/-, Trpv6mt/mt and double mutant Trpc1-/-/Trpv6mt/mt mice. All mice used in this study had 
the same genetic background, i.e. mixed (129SvJ/C57BL/6). Fractured femurs were removed 
and after explanting the screws, they were scanned by SkyScan 1172 µCT. We also compared 
the weight of individual mice immediately before producing the fracture and four weeks later, 
prior to explanting the screw. We observed no significant reduction in weight of mice during 
the healing phase, (supplementary Figure 6-2). The µCT data showed that callus parameters 
remained unchanged in WT and Trpc1-deficient femurs (Figure 3-5) whereas the volume of 
total callus and bone volume, the mineralized portion within the callus were approximately 
50% reduced in Trpv6mt/mt and Trpc1-/-/Trpv6mt/mt mice compared to WT and Trpc1-/- mice 
(Figure 3-5A). A significant increase in mineral density and trabecular number was seen in 
Trpv6mt/mt and Trpc1-/-/Trpv6mt/mt mice compared to WT and Trpc1-/- mice. A significant 
reduction in trabecular separation in Trpv6mt/mt and Trpc1-/-/Trpv6mt/mt mice was observed 
fitting with the increase in trabecular number. The trabecular thickness of callus tissue was 





We also assessed the extent of mineralization by determining the volume of highly and low 
mineralized bone within the callus of all four groups using two different threshold ranges to 
estimate the proportion of highly mineralized callus calculated at the threshold range of 98-
255 and of low mineralized callus at threshold range of 68-97. The amount of highly 
mineralized bone was significantly increased in callus tissue from Trpv6mt/mt and Trpc1-/-
/Trpv6mt/mt mice compared to callus in WT and Trpc1-/- mice. To summarize, fractured femur 
analyses showed significant reduction of total callus volume and a higher proportion of bony 
callus in Trpv6mt/mt and Trpc1-/-/Trpv6mt/mt as compared to callus in wild-type and Trpc1-/- mice 
(Figure 3-5B, C). 
 
Figure 3-5 Analyses of femurs four weeks after fracture. The defined fracture was applied to 
20-weeks old wild-type, Trpc1-/-, Trpv6mt/mt and double mutant Trpc1-/-/Trpv6mt/mt mice. 
Fractured femurs scanned by SkyScan 1172 to evaluate (A) callus parameters determined at a 
grayscale range of 68-255. (B, C) Volume and percentage of highly and low mineralized bone 
within the callus tissue determined at a threshold range of 98-255 (high) and 68-97 (low). Data 
shown as mean ± SD statistically calculated by one-way ANOVA followed by Bonferroni 
multiple comparison test (p<0.05 *, p<0.01 **, p<0.001 ***). The bars represent WT (black), 
Trpc1-/-(green), Trpv6mt/mt (red) and Trpc1-/-/Trpv6mt/mt (blue), with the number of animals for 





3.2 Biomechanical properties of femora 
The µCT data helps in understanding the bone microarchitecture but provides minimal insight 
into the mechanical properties of bone. Therefore, we measured the biomechanical 
properties of intact and fractured femurs by a 3-point bending device (Herath et al., 2015). 
The bones from wild-type animals were compared with Trpc1-/-, Trpv6mt/mt and double mutant 
Trpc1-/-/Trpv6mt/mt mice. As above, all mice used in this experiment were on mixed 
(129SvJ/C57BL6/N) genetic background and twenty-four weeks old. The data revealed 
significant increase in bending stiffness of bones from Trpv6mt/mt and Trpc1-/-/Trpv6mt/mt as 
compared to WT and Trpc1-/- mice (Figure 3-6). These findings correlate to the results of µCT 
data especially the increment of cross-sectional thickness of femurs from Trpv6mt/mt and Trpc1-
/-/Trpv6mt/mt mice compared to wild-type mice (Figure 3-4A).  
Figure 3-6 Bending stiffness of intact femurs 
from 24-week-old wild-type, Trpc1-/-, Trpv6mt/mt 
and double mutant Trpc1-/-/Trpv6mt/mt male 
mice. Bending stiffness (N/mm) was analyzed by 
a non-destructive three-point bending test. Data 
shown as mean ± SD, calculated by one-way 
ANOVA followed by Bonferroni multiple 
comparison test (p-value summary, p<0.05 *, 
p<0.001 ***). The colored bars represent four 
different genotypes: wild-type (black), Trpc1-/-
(green), Trpv6mt/mt(red) and Trpc1-/-/Trpv6mt/mt 
(blue) with the number of animals for each group 
indicated  in the colored square.                                                                                                                       
In conclusion, we observed greatest resistance against the gradually applied force by the 
bones from Trpc1-/-/Trpv6mt/mt mice in comparison to the other genotypes. We also 
determined the bending stiffness of fractured femurs of four different genotype mice after 
explanting the screw. However, no significant difference in bending stiffness was observed 
between all four groups (supplementary Figure 6-3). 
3.3 Primary osteoclasts culture 
The µCT data revealed a reduced trabecular bone volume fraction in femurs of TRPC1 deficient 





primary osteoclasts culture. Up to this aim, I established the differentiation and culture of 
osteoclasts from bone marrow derived cells. After flushing out, the bone marrow cells were 
differentiated in the presence of M-CSF and RANK-L.  Figure 3-7A shows differentiating 
osteoclasts at day two (D2) until day eight (D8), at which largely poly-nucleated osteoclasts 
are present. Trpc1-transcripts are present during differentiation and in mature osteoclasts 
(Figure 3-7B). I also identified transcripts of other members of Trpc subfamily in mature 
osteoclasts (Figure 3-7C) with the exception of Trpc5. My colleague Kai-Markus Busch showed 
that Trpc1 transcripts also present in osteoblasts, outgrown from bone slices (supplementary 
Figure 6-7).    
 
Figure 3-7 Differentiation of primary mouse osteoclast. (A) Representative images of tartrate 
resistant acid-phosphatase (TRAP) stained precursors (day 2 and 4), and matured 
multinucleated osteoclasts (day 6 and 8), (B) RT-PCR of Trpc1 transcripts with total RNA 
isolated from M-CSF and RANK-L untreated (day 0) or M-CSF and RANK-L treated (day 2, 4, 6 
and 8) bone marrow-derived cells, mRNA from brain served as a control, Hprt1 was amplified 
as a positive control and water was used a negative control, (C) RT-PCR of Trpc transcripts with 
total RNA isolated from matured multinucleated osteoclasts (top), and from brain (bottom); 





The TRAP staining experiments showed significantly reduced osteoclasts number in the 
culture from bone marrow derived cells form Trpc1-/- mice as compared to wild-type mice 
(Figure 3-8A, B) although the same number of cells were seeded i.e. 1x105 cells per well of 96-
well plate. This result suggested that in vitro osteoclasts differentiation is impaired in Trpc1-/- 
mice. Using a von Kossa staining, we observed significantly reduced number of resorption pits, 
formed by the osteoclasts derived from Trpc1-/- mice (Figure 3-8C, D) complying with our TRAP 
staining results. These experiments were performed together with my colleague Kai-Markus 
Busch.  
 
Figure 3-8 Primary osteoclast culture. (A) Representative images of TRAP-positive 
multinucleated osteoclasts differentiated from bone marrow cells of wild-type (left panel) and 
Trpc1-/- (right panel) mice, black arrows indicate examples of the multinucleated osteoclasts, 
scale bar = 0.1 mm. (B) Bar graphs indicate the number of osteoclasts in each well as mean ± 
SEM, with three wells per mouse from 13 mice (WT, black) and three wells per mouse from 
12 mice (Trpc1-/-, green). (C) Representative images of von Kossa stained bone (black) showing 
resorbed surface (white) by the activity of differentiated osteoclasts of wild-type (left panel) 
and Trpc1-/- (right panel) mice, scale bar = 1 mm. (D) Bar graphs indicate the percentage of 
resorbed bone in each well as mean ± SEM, with three wells per mouse from 11 mice (WT, 
black) and three wells per mouse from 10 mice (Trpc1-/-, green), significance was calculated 





3.4 Generation of a Trpc1-IRES-Cre (Trpc1-IC) mouse strain 
In previous studies, it has been hypothesized that Trpc1 transcripts are ubiquitously expressed 
(Zhu et al., 1995), (Nilius and Flockerzi, 2014a, b), (Wes et al., 1995). However, it has always 
been very challenging to test this hypothesis because of the following reasons. There is a lack 
of appropriate antibodies to detect TRPC1 protein by immunohistochemistry and no reliable 
TRPC1 ion currents have been measured by patch clamp recordings. To overcome these 
difficulties and to effectively visualize and manipulate Trpc1-expressing cells throughout the 
body in mice, a Trpc1-specific Cre recombinase knock-in (KI) mouse strain had to be generated.   
3.4.1 Strategy for the generation of a Trpc1-IC mouse strain 
In order to generate the Trpc1-IRES-Cre recombinase KI mouse strain (Trpc1-IRES-Cre or 
TRPC1-IC) an “IRES-Cre recombinase-FRT site-neo-FRT site cassette” had to be inserted just 
downstream to the STOP codon by gene targeting. The presence of the IRES-DNA sequence 
downstream the STOP codon should allow generating a bicistronic mRNA under the control of 
the endogenous Trpc1 promoter (Figure 3-9).  
 
Figure 3-9 Strategy for the generation of a Trpc1-IC mouse strain. By homologous 
recombination the “IRES-Cre recombinase (Cre)-FRT-neo-FRT cassette” is introduced 3’ of the 
STOP codon in the last protein coding exon 13 of the Trpc1 gene. It transcribes into bicistronic 
messenger RNA (mRNA), which upon translation yields two independent proteins i.e. TRPC1 
and Cre-recombinase within the same cell. (Black bars depict exon 13, not in scale, unfilled 





These TRPC1-IC mice have to be bred with, for example, eROSA26-GFP reporter mice. The 
litters obtained from this breeding, TRPC1-IC/eR26-GFP animals, will have constitutive GFP 
expression in Trpc1-expressing cells: The Cre-recombinase, co-expressed with Trpc1, will lead 
to excision of the floxed transcriptional termination signal (STOP cassette). As a result, 
eROSA26-GFP-driven transcription of GFP (or other reporters, depending on the type of 
reporter mouse) will occur in TRPC1-IC/eR26-GFP double KI mice (Figure 3-10).    
 
Figure 3-10 Breeding strategy to genetically label Trpc1-expressing cells. Breeding of Trpc1-
IC mice with the eR26-GFP reporter mouse strain will lead to excision of the floxed 
transcriptional termination signal (STOP) cassette, which in turn will activate eROSA26-driven 
transcription of GFP in Trpc1-IC/eR26-GFP double knock-in mice. (Filled triangles represent 
loxP site). The eR26-GFP mouse strain was generated (Wen et al., 2011) and generously 
provided by Prof. Dr. Ulrich Boehm (FR 2.4, Homburg).  
3.4.2 Cloning strategy to generate Trpc1-IC targeting vector 
The Trpc1-IC targeting construct (pAR_11, 12939 bp) is composed of a 5’ Trpc1 homology arm 
followed by an IRES-Cre recombinase cDNA-phosphoglycerate kinase (pgk) promotor driven-
FRT site-neomycin resistance gene (neo)-FRT site cassette- and a 3’ Trpc1 homology arm 
(Figure 3-11). First, the Trpc1 gene organization and sequence was obtained from the 
Ensemble genome browser. The 5’ (3254 bp) and 3’ (2387 bp) homology regions derived from 





synthesized and cloned into the pUC18 by Biomatik (Ontario, Canada) to yield plasmids pAR_7 
and pAR_6 (Figure 3-11A). The AgeI-NotI 5’ homology region (5’ Hom) from pAR_7 was 
subcloned into the AgeI-NotI cut plasmid pAR_6 to yield pAR_8 (8320 bp) (Figure 3-11B). The 
AscI fragment obtained from plasmid pKO-ICF comprising of splice acceptor IRES-Cre 
recombinase-phosphoglycerate kinase promotor-driven FRT-neomycin resistance-FRT 
cassette was subcloned into AscI cut pAR_8 to yield pAR_9 (11763 bp) (Figure 3-11C). The 
cassette was inserted 23 nucleotides downstream to the STOP codon of Trpc1.    
The ‘neo’ cassette was added as a positive selection marker used for the 
identification/selection of ES cell clones having integrated targeting construct.  In the presence 
of geneticin only those cells survive which carry the neomycin resistance gene, that is the gene 
of aminoglycoside phosphotransferase. Geneticin (abbreviated as G418) inhibits protein 
synthesis and kills eukaryotic cells. The aminoglycoside phosphotransferase phosphorylates 
HO-groups of G418 thereby inactivating G418 allowing survival of these cells carrying the 
resistance gene. Finally, phosphoglycerate kinase (pgk)-promoter driven diphtheria toxin A 
fragment (DTA) cassette was subcloned downstream to the 3’ homology: To generate blunt-
ended DNA the RsrII cDNA fragment encoding the cassette, DTA, from plasmid pKOselect 
DTV840 and the NotI cut plasmid pAR_9 were incubated in the presence of T4 DNA 
polymerase, dNTPs and the blunt-ended DNAs were ligated to obtain pAR_11, the final 
targeting vector (12939 bp) (Figure 3-11D).  The DTA was added to the plasmid as a negative 
selection marker to ensure the selection of ES cell clones with correctly integrated DNA. In 
case the targeting construct is randomly integrated, DTA fragment will be translated and kill 






Figure 3-11 Cloning strategy for the generation of Trpc1-IC targeting vector. (A) The vectors 
pAR_7 (5947 bp) and pAR_6 (5082 bp) depicts 5’ homology along with the stop codon and 
3’homology regions, respectively. The fragment 3’ homology arm (2381 bp) is prepared from 
the vector pAR_6 by the restriction enzymes AgeI and NotI and subcloned into AgeI/NotI cut 
vector pAR_7 yielding vector pAR_8 (8320 bp) (B) Internal ribosome entry site (IRES)-Cre 
recombinase cDNA (Cre)-pgk promotor-driven Flp recombination target (FRT) site-neomycin 
resistance gene (neo)- FRT cassette (3444 bp) is prepared from the vector pKO-ICF (6596 bp) 
by the restriction enzyme AscI and subcloned into the AscI cut vector pAR_8 downstream of 
the stop codon yielding vector pAR_9 (11763 bp) (C) The Diptheria toxin A (DTA) fragment 
(1190 bp) is isolated from the vector pKOselect DTV840 (2984 bp) by the enzyme RsrII, blunted 





bp) (D) The final targeting construct pAR_11 is linearized by the restriction enzyme ScaI. Black 
arrows highlight the approximate location of restriction enzymes required in specific cloning 
steps. Location of enzymes is determined by the software Accelrys Gene v2.5. Unfilled 
triangles represent FRT sites.     
The correctness of pAR_11 was confirmed by restriction enzyme cuts followed by agarose gel 
electrophoresis and by nucleotide sequencing on both strands. The pAR_11 was linearized 
with ScaI (Figure 3-12), sent to iTL (ingenious Targeting Laboratory, Ronkonkoma, New York, 
USA) and electroporated there into C57BL/6 ES cells. The representative agarose gel images 
of individual cloning steps are shown in the supplementary Figure 6-4. The vectors pKO-ICF 
and pKOselect DTV840 were generously provided by Prof. Dr. Ulrich Boehm (FR 2.4, Homburg) 
and Prof. Dr. Thomas Jentsch (MDC/ FMP, Berlin), respectively.   
 
Figure 3-12 Linearized final targeting plasmid, pAR_11. Agarose gel electrophoresis of 
pAR_11 cut by ScaI (+) and non-cut super-coiled DNA (-), marker was applied on the right lane.    
3.4.3 Identification of precisely integrated ES cell clones by Southern blotting   
The linearized targeting construct ‘pAR_11’ was electroporated into C57BL/6 ES. The 5’ and 3’ 
homology regions of the targeting construct allow integration at the Trpc1 gene locus by 
homologous recombination. After selection with G418 and DTA a total number of 288 ES cell 
colonies were isolated by iTL and lyophilized replicas sent to Homburg for Southern blotting. 
For the identification of correctly integrated ES cell clones, a Southern blot strategy was 
established based on three probes, the 5’-probe and the 3’-probe, both probes located 
outside of the homology regions, and the neo-probe, present within the targeting construct 
(Figure 3-13A).  Initially, I checked 128 ES cell clones by the 5’-probe and 93 clones were found 






Figure 3-13 Southern blot analysis for the selection of precisely integrated ES cell clones. (A) 
Southern strategy: from top to bottom, Trpc1-wt allele, Trpc1-targeting vector and targeted 
recombination of the Trpc1 locus (F2 allele) indicated. Translated exons (not in scale) are 
shown as black boxes. The targeting vector is composed of an internal ribosome entry site 
(IRES) element followed by a Cre, the coding sequence of Cre recombinase and a neomycin 
resistance gene (neo) cassette flanked by FRT, the Flippase recombination target sites (unfilled 
triangles) has been inserted after the stop codon present within exon 13. Dotted lines in 
between the wt allele and targeting vector represent the region of homologous 
recombination. The sites for restriction enzymes (S, SacI, H, HindIII) and location of 5’-, neo- 
and 3’-probes used for Southern blot hybridization are indicated. The predicted fragment sizes 
in both wt and mt alleles are shown by the arrows. (B) Southern blot: Representative images 
indicate the expected bands in the genomic DNA cut by SacI (5’ probe) and HindIII (neo and 
3’probes) from three independent recombinant Trpc1-IC ES-cell clones (clone numbers 1.3B4, 
1.3D2 and 1.3D3) using 5’-, neo- and 3’-probes. All representative three ES cell clones show 
Trpc1-wt and -mt alleles.  
Thus, the calculated recombination efficiency was approximately 73%. The 5’-probe labelled 
SacI fragments of genomic ES cell DNA of 4.7 Kb and 7.5 Kb in wt and mt alleles respectively. 
Thirty-two clones out of those 93 were tested with both the 3’-probe and the neo-probe. The 
3’-probe labelled HindIII fragment of 5.3 Kb in the wild-type and 6.4 Kb in the mutant allele. 





construct is integrated only once within the genome (Figure 3-13B). Twenty-seven out of 32 
clones were found to be positive. All three probes confirmed precise integration of the 
targeting construct at the Trpc1 locus by homologous recombination. Five out of 27 were 
selected, expanded and karyotyped for chromosome count analysis (Table 3-3). 





1 1.3B2 78 
2 1.3B4 77 
3 1.3D2 100 
4 1.3D3 86 
5 1.3E4 75 
Table 3-3 Chromosome count performed by iTL (karyotype result) for five selected ES cell 
clones for the generation of Trpc1-IC KI mouse strain. 
3.4.4 Identification of Trpc1-IC mice by PCR based genotyping  
Three ES cell clones (clone numbers 1.3D2, 1.3B4 and 1.3B2) out of five selected based on 
their karyogram were injected into BALB/c blastocysts. The summary of injections performed 
in Interfakultäre Biomedizinische Forschungseinrichtung (IBF) Heidelberg University and iTL 
(USA) is given in the supplementary section (Table 6-6). Subsequently these blastocysts were 
implanted into the uterus of pseudopregnant C57BL/6 foster mothers. All three implantations 
resulted in eight chimeras. These pups were the F0 generation. All chimeras were derived from 
clone 1.3B4. The percentage of chimerism in F0 progeny was estimated based on coat color 
distribution. The success of a gene targeting depends on the maintenance of a mutant allele 
in the gametes (sperms or eggs) i.e. germline transmission. In this way, the mutation can be 
transmitted over generations. Therefore, the next step was to backcross the highly chimeric 
animals with C57BL6/N wild-type mice to check if the mutant allele has been inherited. The 
presence of the F2 allele in the offspring from chimera was tested by PCR based genotyping 
using specific primers amplifying the locus of integration within exon 13 and the FRT sites 
(Figure 3-14B). Our results showed the presence of heterozygous mice in F1 generation.  
Images of selected heterozygous mice are shown in Figure 3-15. They are viable, healthy and 
show no obvious abnormalities. One of the three ES-cell (1.3B4) derived mouse lines was used 







Figure 3-14 Genotyping strategy to follow successful recombination. Schematic 
representation of the genotyping strategy: (A) Trpc1 wt allele shows three exons (11-13), filled 
boxes, not in scale, approximate location of primer combination is shown spanning over the 
exon 13 to identify the wt allele by PCR, (B) Trpc1 F2 allele, (F2 because of two FRT sites (open 
triangles)) contains the IRES-Cre-neomycin resistance cassette, neo, flanked by two FRT sites 
inserted after the stop codon in the middle of exon 13. Arrows indicate position of forward 
and reverse primers used for PCR, (C) Trpc1 F1 allele obtained upon Flp-mediated excision 
shows IRES-Cre and the single remaining FRT site, (D) table (top) shows the forward (F) and 
reverse (R) primer combinations used for the PCR reactions 1 to 5 along with the expected 
fragment sizes (bp). Representative agarose gel images (middle and bottom) show the PCR 
based genotyping results for the identification of mice carrying wt, F2 and F1 alleles. Numbers 
indicate PCR reaction from the table.   
                        
Figure 3-15 Trpc1-IC heterozygous mice in F1 generation. Representative images show female 
(left) and male (right) heterozygous mice identified by genotyping PCR. All mice resulted from 
the injection of ES cell clone number 1.3B4 into Balb/c blastocysts subsequently implanted in 





Previous studies have shown that the neo cassette contains cryptic splice sites and thus its 
presence within the genome could interfere with the expression of neighboring genes (Meyers 
et al., 1998). Therefore, the neo cassette has to be removed once the targeting construct is 
successfully integrated within the endogenous DNA sequence to avoid a possible 
hypomorphic allele (Jacks et al., 1994). In our targeting plasmid, the neo cassette is flanked by 
FRT sites. Mice carrying the F2 allele (Figure 3-14B) were bred with Flp deleter mice, 
ubiquitously expressing Flpe recombinase as a transgene (Dymecki, 1996). The resultant pups 
were genotyped using PCR primers to confirm the deletion of the neo cassette, in terms of the 
targeting construct recombination results in the Trpc1 F1 allele or Trpc1-IRES-Cre-neo- allele 
(Figure 3-14C). In terms of mice, the new Trpc1-IRES-Cre strain is also dubbed as “Trpc1-IC”. 
Currently, the breeding of Trpc1-IC mouse strain is successfully operational in our animal 
facility. Homozygous pups born are healthy, fertile and without any obvious phenotypic 
abnormalities. These animals can now be crossed with one of eROSA26-reporter mouse 
strains provided by Prof. Dr. Ulrich Boehm (FR 2.4, Homburg) in order to manipulate or to 
visualize Trpc1-expressing cells. (Figure 3-10) shows the breeding scheme with the eROSA26-
GFP  reporter strain (Wen et al., 2011) yielding Trpc1-IC/eR26-GFP mice, with constitutive 
GFP expression in Trpc1 expressing cells. Experiments performed on the pituitary, obtained 
from Trpc1-IC/eR26-GFP mice by my colleague Dr. Hongmei Wang, enabled us to visualize 
the TRPC1 expression pattern in pituitary cells and to specifically characterize the Trpc1-













3.5 Generation of a conditional Trpc1 mouse strain 
In the year 2007, Alexander Dietrich et al. reported the generation of a Trpc1 global KO mouse 
model and until present, it has been extensively studied to characterize the role of TRPC1 in 
various organs (Dietrich et al., 2007). However, using a Trpc1 conventional KO mouse strain, 
it is quite challenging to explain the cell- or tissue-specific role of Trpc1. Thus, in order to 
determine the specific role of Trpc1 in any desired cell type or any organ such as bone cells or 
bone, I have generated a mouse line carrying a conditional Trpc1 allele, which could be bred 
with any cell/tissue-specific Cre-recombinase mouse strain to generate Trpc1 deletion in a cell 
specific manner.    
3.5.1 Strategy for the generation of a conditional Trpc1 mouse strain 
We developed a cloning strategy as outlined in the (supplementary Figure 6-6) for the 
generation of a conditional Trpc1 mouse strain. The loxP sites should flank exon 8 and 9, which 
is part of the ion-conducting TRPC1 pore. The molecular biology techniques employed for 
getting the targeting construct are identical to those described above for the cloning of the 
targeting vector required to generate the Trpc1-IRES-Cre mouse strain. However, abundant 
repetitive DNA sequences prevented amplification of the 3’ homology region. After several 
trials, I abandoned this targeting strategy.  
Instead, we decided to use a targeting construct from EUCOMM (PG00239_Z_4_A03) with a 
floxed exon two of the Trpc1 gene. In the mouse (mus musculus) genome, exon 2 of Trpc1 
transcript, Trpc1-204, (transcript ID ENSMUST00000189137.6) consists of a 155 bp long 
nucleotide sequence (5’upstream sequence, start:end, 95,743,351:95,743,197) as indicated in 
the Ensemble genome browser. Deletion of this particular exon would lead to a shift in the 
reading frame causing a premature termination during translation of the TRPC1 protein due 
to nonsense mutations.   
We obtained the targeting construct, C1Z_21361 bp, from EUCOMM and had it sequenced on 
both strands. The targeting construct consists of 5’ (5544 bp) and 3’ (3616 bp) homology 
regions for the homologous recombination at the Trpc1 gene locus in the mouse. The 5’ 
homology arm was followed by a pair of consensus FRT-sites. The cassette has been inserted 
in between the FRT-sites consisting of splice acceptor (SA) site- IRES-(bacterial beta-





actin promoter-driver neo cassette. Exon two of Trpc1 is flanked by loxP sites and DTA has 
been inserted as a negative selection marker (Figure 3-16). 
 
Figure 3-16 Targeting vector (EUCOMM; PG00239_Z_4_A03) for the generation of a 
conditional Trpc1 mouse strain. The targeting vector, C1Z_21361 bp consists of 5’ (5544 bp) 
and 3’ (3616 bp) homology arms and in between flippase recombination target (FRT) site-
splice acceptor (SA)- internal ribosome entry site (IRES)-lacZ-polyadenylation (pA) signal-loxP 
site-neo cassette-FRT is shown. The exon two is flanked by loxP sites. Diphtheria toxin A (DTA) 
is located downstream of the 3’homology arm. Approximate site of the restriction enzyme 
AsiSI is indicated by the arrow. Unfilled and filled triangles show FRT and loxP sites 
respectively.  
This vector (Figure 3-16 and 3-17) was used for gene targeting in C57BL/6 ES cells to generate 
ES-cells heterozygous for the inserted mutation; the ES cells should carry the wild-type allele 
and the Trpc1 L3F2 allele: L3 stands for three loxP sites, F2 stands for two FRT sites. By crossing 
L3F2 mice with Flp recombinase deleter mice, a Trpc1 flox allele should be generated (Figure 
3-17B). In the floxed allele, exon two of the Trpc1 gene is flanked by two loxP sites, within the 
second and third introns, respectively. Subsequent crossing of Trpc1 flox mice with tissue 
specific Cre recombinase deleter mouse lines should lead to the deletion of exon two (Figure 
3-17C). 
Using this targeting vector, the L3F2 allele can also be used to generate a lacZ reporter mouse 
strain. By crossing mice bearing Trpc1 L3F2 allele with Cre recombinase deleter mice, a Trpc1 
KO IRES-lacZ allele can be generated which comprises of SA-IRES-lacZ cassette (Figure 3-17D). 
By splicing, the IRES-lacZ sequence should be attached to the exon one of the Trpc1 gene due 
to the presence of splice acceptor (SA) site. The IRES element leads to the formation of a 
bicistronic mRNA. The first mRNA encodes exon one which upon translation runs into a 
premature stop. The second mRNA encodes the β-galactosidase encoded by the lacZ gene. As 





galactosidase should be present only in cells originally expressing Trpc1 and now lacking Trpc1. 
That means β-galactosidase enzyme activity can be used to identify Trpc1-KO cells by adding 
its substrate ‘X-gal’ and subsequent detection of blue coloration. By this strategy, we generate 
a complementary mouse strain to the Trpc1-IRES-Cre mouse. The Trpc1-IRES-Cre mouse can 
be bred with reporter strains such as eR26-GFP in order to visualize Trpc1-expressing cells by 
GFP (Figure 3-10); with the “lacZ” strategy, we are able to visualize Trpc1 KO cells. 
 
Figure 3-17 Targeting strategy for the generation of conditional Trpc1 mouse strain. 
Schematic representation of a targeting strategy (A) Trpc1-wt allele, Trpc1-targeting vector 
and targeted recombination (L3F2 allele) indicated. Translated exons (not in scale) are shown 
as black boxes, dotted lines represent the region of homologous recombination. The targeting 
vector consists of consensus FRT sites (unfilled triangles), in between these sites SA-IRES-lacZ-
loxP site-neo cassette is located, exon two flanked by loxP sites (filled triangles) is shown. Flp-
mediated excision, left panel, will lead to (B) Trpc1 L2F1 allele (L2 because of two loxP sites 
and F1 due to a single FRT site) consists of a FRT site downstream of the exon one and a floxed 
exon two, Cre-mediated excision of Trpc1 L2F1 allele will lead to (C) Trpc1 L1F1 (L1 because of 
one loxP sites and F1 due to of a single FRT site) or Trpc1 KO allele contains FRT and loxP sites 
present in between exons one and three is indicated. (D) Cre-mediated excision of Trpc1 L2F1 
allele, right panel, will lead to Trpc1 KO IRES-lacZ allele consists of a FRT site-SA-IRES-lacZ-loxP 





3.5.2 Identification of correctly targeted ES cell clones by PCR and Southern 
blotting  
The ‘C1Z_21361 bp’ targeting vector was confirmed by sequencing on both strands and then 
linearized by the restriction enzyme AsiSI (Figure 3-18). The linearized plasmid was 
electroporated into the C57BL/6 ES cells by ingenious Targeting Laboratory (iTL). 
 
Figure 3-18 Linearized targeting construct, C1Z. The representative agarose gel image shows 
the plasmid C1Z, cut (+) by AsiSI and super-coiled non-cut (-). Arrow indicates the expected 
fragment size (21361 bp), size marker in kilo base pairs (Kb) is indicated.    
A total number of 288 neomycin-resistant ES cell colonies were picked by iTL and sent to us 
for screening by PCR and Southern blotting. The targeting construct, C1Z, has three loxP sites 
and the exon two is flanked by the second and third loxP sites (Figure 3-16). The third loxP site 
is located close to the 3’ homology arm and thus there were greater chances of its loss during 
homologous recombination. Therefore, it was crucial to verify the insertion of the third loxP 
site into the target sequence. As Southern blotting is not an appropriate method for the 
detection of 34 bp loxP site in the mutant allele, I designed a PCR strategy with a primer 
combination, AR-74/AR-75, spanning over the third loxP site. Initially, I performed PCR on 96 
ES cell clones and 88 clones were found positive i.e. showing both wt and mutant fragments 
(Figure 3-19). The representative agarose gel (Figure 3-19C) shows a PCR result of a wild-type 
ES clone and a clone where the third loxP site is present. Out of 88 PCR-positive clones, I 






Figure 3-19 PCR strategy for the identification of third loxP site insertion in the mutant allele. 
(A) PCR strategy: top, Trpc1 wt allele containing exons (black boxes), not in scale, and position 
of forward primer, AR-74 and reverse primer, AR-75; bottom, Trpc1 L3F2 allele shows the 
targeting construct, present downstream of the exon one, containing Flippase recombination 
target (FRT) site-splice acceptor (SA)-internal ribosome entry site (IRES)-lacZ-loxP site-neo 
cassette-FRT site-consensus loxP sites. Forward primer, AR-74 and reverse primer, AR-75 
spanning over third loxP site. Unfilled triangles show FRT sites while filled triangles depict loxP 
sites. (B) Table shows the expected band sizes in wt and L3F2 alleles obtained by PCR using 
primers AR-74 and AR-75. (C) Representative agarose gel image shows a single band (250 bp) 
in wt allele, representing the two wt alleles and two bands (250 and 282 bp) in L3F2 allele, 
representing one wt and one mutant allele both differing in the loxP site present in the mutant 
allele. 
In order to identify correctly recombined ES cell clones, I designed a Southern strategy based 
on three probes namely a 5’-, and a 3’-probe, both external to the targeted sequence and an 
internal neo’-probe, present within the targeting construct showing singular integration of the 
targeting vector in the ES cell genome (Figure 3-20). Thirty-two ES cell clones positive for the 
third loxP site were analyzed with all three probes by Southern blot. The 5’-probe hybridized 
to a 16.2 Kb band and a 13.9 Kb band in StuI cut DNA respectively, the expected DNA 
fragments from the wild-type allele and the mutant allele (Figure 3-20B). The 3’-probe 
hybridized to PflMI cut DNA with 6.4 Kb and 9.7 Kb band sizes in wt and mt alleles respectively. 
The internal probe, neo-, hybridized to PflMI cut DNA; the size of the band was 9.7 Kb 






Figure 3-20 Southern blot analysis for the generation of a conditional Trpc1 mouse strain. 
(A) Southern strategy: from top to bottom, Trpc1- wt allele, Trpc1-targeting vector and 
targeted recombination (L3F2 allele) indicated. Translated exons (not in scale) are shown as 
black boxes. The targeting vector is composed of 5’ homology arm followed by a pair of 
consensus Flippase recombination target (FRT) sites. The cassette inserted in between the FRT 
sites consists of splice acceptor (SA) site-internal ribosome entry site (IRES)-lacZ cDNA-loxP 
site and a neomycin resistance gene cassette (neo). Exon two of the Trpc1 gene is flanked by 
loxP sites and diphtheria toxin A (DTA) as a negative selection marker is shown. Dotted lines 
in between the wt allele and targeting vector represent the regions of homologous 
recombination. Restriction enzyme sites (S, StuI, P, PflMI) and location of 5’-, neo- and 3’-
probes used for Southern blot hybridization are indicated. The predicted fragment sizes in 
both wt and mt alleles are shown by the arrows. (B) Southern blot: Representative images 
indicate expected bands in the genomic DNA cut by StuI (5’probe) and PflMI (3’ and neo probe) 
from three independent recombinant Trpc1 ES-cell clones (clone numbers 3.1B2, 3.1D4 and 
3.2D2) using 5’-, neo- and 3’-probes. All representative three ES cell clones show Trpc1-wt and 
-mt alleles.  
Twenty-four ES cell clones out of 32 were positive with all three probes and six out of those 










1 3.1B2 71 
2 3.1D3 86 
3 3.1D4 75 
4 3.2A1 79 
5 3.2D2 85 
6 3.2D3 86 
Table 3-4 Chromosome count performed by iTL (karyotype result) for selected six ES cell 
clones for the generation of the conditional Trpc1 KO mouse strain.  
3.5.3 Identification of Trpc1-L3F2 mice by PCR based genotyping 
Five out of six ES cell clones, selected on the basis of PCR, Southern and karyogram analyses, 
were injected into BALB/c blastocysts, and subsequently transplanted into the uterus of 
C57BL/6 pseudopregnant foster mothers. The summary of injections performed in 
Interfakultäre Biomedizinische Forschungseinrichtung (IBF) Heidelberg University or iTL (USA) 
is given in the supplementary section (Table 6-7). Only two out of five implanted ES cell clones 
(clone numbers 3.1D4, 3.2D2) resulted into chimeric progeny (Figure 3-21). 
                   
Figure 3-21 Chimeric mice. Representative images show the chimeric progeny resulted from 
the injection of Trpc1-floxed allele positive-ES cell clone number 3.2D2 (left) and 3.1D4 (right).  
The percentage of chimerism was estimated based on coat color distribution. Brown/black 
coat color derives from the mutant ES cells and white coat color from the Balb/c blastocysts.  
Highly chimeric mice derived from two independent ES cell clones were bred with C57BL/6 
WT mice yielded the F1 progeny. The next step was to differentiate between the WT and 
heterozygous pups. Therefore, a genotyping strategy was designed using various primer 





(Figure 3-22A). A representative agarose gel image (Figure 3-22C) shows the PCR genotyping 
result of a WT animal and a mouse, which is heterozygous for the L3F2 allele.  
 
 
Figure 3-22 Genotyping strategy to identify the Trpc1-L3F2 allele and to genotype mice. (A) 
Genotyping strategy: Trpc1 wt allele shows three coding exons (1-3, black boxes, not in scale) 
approximate location of primer combinations is shown spanning over the exon two to identify 
the wt allele by PCR. Trpc1 L3F2 allele contains consensus FRT sites (unfilled triangles), in 
between the FRT sites, SA-IRES-lacZ-loxP site-neo cassette is shown. Exon two is flanked by 
loxP sites (filled triangles), arrows indicate position of forward and reverse primers used for 
PCR. (B) Table (top) shows the forward (F) and reverse (R) primer combinations used the PCR 
reactions along with the expected sizes. (C) Representative agarose gel image shows the PCR 
results for the identification of mice carrying wt and L3F2 alleles. Numbers indicate PCR 
reactions from the table. 
By using PCR genotyping, we identified heterozygous pups in the F1 generation bearing L3F2 
allele, indicative of successful germline transmission (Figure 3-23). 
              
Figure 3-23 Conditional Trpc1 heterozygous mice in F1 generation. Representative images of 
heterozygous mice identified by genotyping. Mice shown on left and right side resulted from 





3.5.4 Generation of Trpc1 flox mice 
The heterozygous L3F2 mice serve as a basis for the generation of Trpc1-flox mice. Currently 
heterozygous L3F2 mice are being crossed with Flp deleter mice to remove the FRT flanked 
SA-IRES-lacZ-loxP-neo cassette resulting in a floxed L2F1 allele (Figure 3-24B). First pups were 
born and PCR based genotyping revealed the generation of mice bearing L2F1 allele. Figure 
shows a representative PCR genotyping result of a Trpc1+/flox animal, which is also positive for 
Flp recombinase (Figure 3-24C). Next step will be backcrossing with C57BL6/N wild-type mice 
to get rid of the Flp gene. The resulting Trpc1+/flox Flp- mice can be used for crossing with a 
osteoclasts specific Cre mouse lines e.g. a TRAP- or Cat K- Cre mouse lines (Chiu et al., 2004) 
to generate an osteoclast specific Trpc1 KO mouse strain. 
 
Figure 3-24 Generation of Trpc1 flox mice. Breeding strategy to generate Trpc1 flox mice: (A) 
Trpc1 L3F2 allele contains three exons (1-3), black boxes (not in scale). The targeting construct 
consists of consensus FRT sites (unfilled triangles), in between these sites, SA-IRES-lacZ-loxP 
site-neo cassette is located, exon two flanked by loxP sites (filled triangles) is shown. Flp-
mediated excision will lead to (B) Trpc1 L2F1 allele consisting of a FRT site downstream of the 
exon one and a floxed exon two. (C) Table (top) shows the forward (F) and reverse (R) primer 
combinations used for the PCR reactions along with the expected sizes; a representative 
agarose gel image (bottom) depicts the PCR results for the identification of mice carrying L2F1 
and wt alleles. Both animals are positive for the Flp recombinase as shown in reaction three. 
Numbers indicate PCR reactions from the table. (D) Cre-mediated excision of Trpc1 L2F1 allele 
will lead to Trpc1 L1F1, which is a Trpc1 KO allele, containing singular FRT and loxP sites 






In my thesis, I have generated two mouse strains, TRPC1-IRES-Cre mice and mice carrying a 
conditional Trpc1 allele. Both mouse strains will allow dissecting the physiological and 
pathophysiological roles of Trpc1 in the living organism. In order to characterize the 
physiological function of Trpc1 in bone, I established µCT analysis of long bones, a femur 
fracture model and the methods to differentiate osteoclasts and to characterize their 
function. In the following, I will first discuss the contribution of Trpc1 to bone function, 
followed by a discussion of the two mouse strains, which I have generated.       
4.1 Contribution of TRPC1 to bone function 
Although the TRPC1 cDNA was the first mammalian cDNA which has been cloned (Wes et al., 
1995), (Zhu et al., 1995), it is still an open question whether TRPC1 itself forms a functional 
channel or whether it is a part of a heteromeric TRP channel complex. In brain and in 
hippocampal neurons TRPC1 is a part of heteromeric TRPC4/TRPC1, TRPC5/TRPC1 or 
TRPC5/TRPC4/TRPC1 channels (Broker-Lai et al., 2017). In heterologous expression systems, 
including cell culture cells such as HEK293 cells or oocytes TRPC1 also forms heterotetrameric 
channels with TRPC4, TRPC5 but also with TRPV4 or TRPV6. Especially TRPV6 has been shown 
to negatively interfere with functional TRPC1 or vice versa (Courjaret et al., 2013), (Schindl et 
al., 2012) . Compared to the broad Trpc1 gene expression the Trpv6 gene expression is quite 
restricted, especially to epididymis, placenta, pancreatic acinar cells and bone.  
Both Trpv6 and Trpc1 transcripts have been identified in various immortalized bone cells. For 
instance, we could identify Trpc1 transcripts in a number of human osteoblast-like cells such 
as SAOS-2, U-2 OS, SK-N-SH and MG-63 (Supplementary Figure 6-7), whereas Trpv6 transcripts 
have been identified in the murine KS483 and the human SV-HFO osteoblast-like cells (van der 
Eerden et al., 2012) and in the murine osteoclast-like cell-line RAW264.7 (van der Eerden et 
al., 2012). More important, van der Eerden et al. and Ong et al. have shown that either 
transcript is expressed in cells derived from bone in living mice, but whether or whether not 





We decided to answer this question by two approaches: First, we wanted to confirm that 
transcripts of both genes are expressed in bone. In case, the transcripts are present we wanted 
to study whether deletion of either gene provokes a bone phenotype. If there would be a 
phenotype, it would be worthy to go back and analyze bone function and bone cell function 
in detail.  
To get an answer to question one, I performed RT-PCR using RNA from crushed bone as a 
template. By this approach, I amplified the full-length protein coding 2879 bp cDNA of Trpc1 
(Figure 3-3A) and a 242 bp fragment of Trpv6 (Figure 3-3D). These results confirmed that 
TRPC1 and TRPV6 are expressed in bone. TRPC1 gene-deficient (KO) mice are available in the 
laboratory as a part of collaboration with Alexander Dietrich (München) and Lutz Birnbaumer 
(Buenos Aires), as well as TRPV6 mutant mice, which have been generated in our group 
(Weissgerber et al., 2011), (Weissgerber et al., 2012). TRPV6 mutant mice carry a point 
mutation, which renders the TRPV6 channel non-functional; they behave like TRPV6 KO mice 
also generated in our group (Weissgerber et al., 2012). Next, we thought about a bone 
phenotype. Using a Bruker µCT system (SkyScan 1172) available at the Institut für Klinisch-
Experimentelle Chirurgie, Universität des Saarlandes, Homburg, we decided to look for a 
phenotype in long bones by comparing the femurs from wild-type, Trpc1-/-, Trpv6mt/mt and 
Trpc1-/-/Trpv6mt/mt mice. 
Mice have been extensively studied using µCT to determine the bone structure at the finest 
resolution. However, there are several considerations, both mouse- and scanning system-
related, that must be taken into account before starting the experiment. Mouse related 
factors include the effect of age, gender, and genetic background (Halloran et al., 2002), 
(Wergedal et al., 2005). The µCT-related technical aspects include image resolution, X-ray 
source voltage and current, filter type and thickness, exposure time and application of beam 
hardening corrections. We aimed to establish a consistent way of determining the cortical and 
trabecular bone microarchitecture in line with the guidelines published by Bouxsein (Bouxsein 
et al., 2010).  
Genetic heterogeneity has an effect on the bone phenotype and has to be considered when 
analyzing the bone parameters (Jilka, 2013). In our animal facility, mice are available on two 
genetic backgrounds, either as C57BL/6 strain or as mixed 129SvJ/C57BL/6 strain. Like human 





analyzed femurs of wild-type mice of the two genetic strains at two ages, at 12 and at 24 
weeks of age. For this basic experiment, we have restricted our studies only to male mice to 
avoid any influence of recurring physiological changes induced by reproductive hormones in 
females (Halloran et al., 2002). The settings for µCT scanning were kept constant throughout 
the study. For the cortical bone analyses, the region of interest covered fifty 6.5 µm cross-
sections exactly in the middle of the femur shaft irrespective of age (Figure 2-5Aa, Ba). For the 
trabecular bone analyses, cross-sections in the region of secondary or mature spongiosa have 
been used where trabeculae are stable, avoiding the contamination of primary spongiosa as 
much as possible (Figure 2-5Ab, Bb). Accordingly, I reduced the “offset” for analyzing 
trabecular bone from 24-week-old mice compared to the measurements of bones from 12-
week-old mice (Figure 2-5Bb), although at these two ages, 12- and 24-week, this adjustment 
yielded identical values of trabecular bone parameters as if taken the 12-week or 24-week 
offset for both ages (data not shown).  
As expected femur length increased with age up to the 12th week in B6, but not in mixed 
(Figure 3-1D, E) and there was an additional increase from the 12th to the 24th week. The 
cortical bone parameters such as endocortical volume and perimeter increased with age in 
bones of mice on B6 background (Figure 3-2A) but not in bones of mice of mixed genetic 
background. In comparison to the cortical bone parameters, we have found more prominent 
differences in trabecular bone parameter with an advancing age in wild-type mice on mixed 
genetic background with considerable loss of bone volume and trabecular number (Figure 3-
2B). Considering these parameters, B6 femurs were not as much affected. Thus, initial 
investigation emphasizes the need, only to compare mice on an identical genetic background. 
For comparing the bone phenotype of Trpc1-/-, Trpv6mt/mt, Trpc1-/-/Trpv6mt/mt and wild-type 
mice, we therefore bred the respective genotypes on the uniform mixed background and 
consecutively analyzed femurs of 24-week-old male mice. Femur length was shorter in 
Trpv6mt/mt and Trpc1-/-/Trpv6mt/mt mice but not in Trpc1-/- mice when compared to femur length 
of wild-type mice. The cortical bone phenotype in Trpv6mt/mt and Trpc1-/-/Trpv6mt/mt mice 
compared to wild-type and Trpc1-/- mice is more prominent as indicated by reduction in 
endocortical volume and significant increase in cross-sectional thickness (Figure 3-4B) of 
femurs. In the double mutant Trpc1-/-/Trpv6mt/mt mice, we have observed cortical bone 





results do not fully agree with the findings that cortical and trabecular parameters remained 
unchanged in Trpv6 mutant femurs as compared to WT mice (van der Eerden et al., 2012). 
However, the study by van der Eerden et al. have also reported reduced femur length and 
reduced endocortical volume (van der Eerden et al., 2012). Our results suggest a thicker 
cortical bone in Trpv6mt/mt and Trpc1-/-/Trpv6mt/mt mice, indicative of increased mechanical 
strength. Although µCT parameters such as polar moment of inertia enables us to predict 
mechanical properties of the bone (Shefelbine et al., 2005), we performed three-point 
bending stiffness test to directly monitor the mechanical properties of the femurs (Allen and 
Burr, 2014). Our results show that a significantly elevated force (N) is required for bending 
bones from Trpv6mt/mt and Trpc1-/-/Trpv6mt/mt mice (Figure 3-6) which is in agreement with the 
expectations of the µCT data.  
Different to the cortical bone, the trabecular bone parameters are more affected in femurs 
from Trpc1-/- mice: The bone volume fraction, the mineral density and the trabecular thickness 
is reduced as compared to wild-type femurs. The trabecular separation and trabecular pattern 
factor are increased fitting with the reduced bone volume fraction as expected (Figure 3-4C). 
Our data from the femur bone analyses from 12-week-old WT and Trpc1-/-mice on B6 
background (supplementary Figure 6-8) comply with the trabecular phenotype observed in 
mice on mixed genetic background. In summary, these findings confirmed the effect of TRPC1 
on bone microarchitecture independent of the genetic heterogeneity. Our results are in 
contrast with the findings from the group of Leonidas Tsiokas, which showed significantly 
increased trabecular bone mass, whereas all other parameters remained unchanged (Ong et 
al., 2013).  At least three reasons might explain these differences: Ong et al. showed µCT 
analysis performed on the tibiae from 12-week-old mice, the µCT scanning settings have not 
been fully described and might have been different, and the genetic background of the mice 
analyzed is not known.   
The trabecular number is increased in Trpv6mt/mt femurs and, again, data indicate a dominant 
effect of the TRPV6 mutation on the Trpc1 KO, abrogating the TRPC1 phenotype. In summary, 
these data indicate that deletion/mutation of TRPV6 cannot be compensated by the deletion 
of TRPC1 whereas the effect of Trpc1 deletion on trabecular bone was compensated by the 





Those findings prompted us to investigate the involvement of these channel subunits in a 
functional assay, in healing of a defined femur fracture (Histing et al., 2011). Fracture healing 
is a complex phenomenon, which begins with the inflammatory response and involves a 
variety of cellular components, growth factors and cytokines (Stegen et al., 2015). Osteoclasts 
perform cartilage resorption and remodeling while osteoblasts form new bone and together 
these are the two main key players in the healing process of a fractured bone (He et al., 2017). 
We have used a closed femur fracture model in our studies where the ends of a broken femur 
are stabilized by a screw (Figure 2-1). Although some cells of the intramedullary cavity could 
get flush out, and thereupon might interfere with the healing mechanism. During the fracture 
healing, the periosteal and endosteal callus tissue, surrounding the cortical bone, provides 
mechanical stability to the fractured bone. Therefore, for the precise determination of callus 
parameters, it is mandatory to select all callus tissue for analyses. Unfortunately, currently 
there is no reliable algorithm available for the automatic isolation of the region of the callus, 
therefore I have selected the callus region of interest manually by drawing the borders of the 
callus (Supplementary Figure 6-5).  
The µCT data obtained show a significantly reduced amount of callus volume in fractured 
femurs of Trpv6mt/mt and Trpc1-/-/Trpv6mt/mt mice. The percentage of highly mineralized bony 
callus is also increased in these mice, an indicative for the rapid healing process. The trabecular 
parameters such as trabecular number and the estimate of mineral density is also increased 
in femurs from Trpv6mt/mt - and Trpc1-/-/Trpv6mt/mt mice, indicative of more bony callus (Figure 
3-5). However, this “bony callus” does not translate into increased mechanical strength 
because we observed no difference in the bending stiffness of the fractured bones from all 
four groups using three-point bending test (Supplementary Figure 6-3). It must be noted that 
a four-point bending test might be preferable for estimation of the bending stiffness in 
fractured bones because of a more adequate application of the bending forces to the femur 
(Allen and Burr, 2014): The surface of the bony callus is not smooth and the force transducer 
hits exactly the fractured region of the femur using the three-point bending apparatus.  
The µCT findings point to a remarkable trabecular phenotype in Trpc1-/- mice and as 
osteoclasts and osteoblast are major players in bone modelling and remodeling to construct 
the overall bone structure, we decided to elucidate the role of Trpc1 in osteoclast formation 





observed a significant reduction in osteoclast number. This reduction was mirrored by less 
bone resorption monitored by von Kossa stained pits and trails (Figure 3-8). Our observations 
from the osteoclast culture experiments contrast with the µCT results where we have 
observed reduced trabecular numbers. Our culture experiments also contrast with the 
published results from the group of L. Tsiokas: Ong et al. have shown no difference in 
osteoclast differentiation and resorption in the cultured cells from wild-type and Trpc1-/- mice 
(Ong et al., 2013). As osteoclasts and osteoblasts both play a vital role in the fracture healing, 
compromised osteoclastogenesis would slow down the cartilage resorption ultimately 
resulting in delayed fracture healing. On the other hand, the fractured bone data has shown 
no significant differences in callus tissue parameters from Trpc1-/- mice compared to wild-type 
mice. Therefore, further attention must be paid towards primary osteoblasts, which do 
express Trpc1 (supplementary Figure 6-7B), and might essentially contribute to the observed 


















4.2 Generation of a Trpc1-IC KI mouse strain  
Gathering conclusive data on the presence of TRPC1 protein in a given cell is challenging 
because of the lack of reliable TRPC1-antibodies for immunohistochemistry as well as the 
absence of authentic TRPC1-mediated currents in patch-clamp experiments. In order to 
overcome these limitations, there was a critical need of visualizing Trpc1-expressing cells in 
mice including TRPC1-expressing bone cells.  
I generated a novel TRPC1-IRES-Cre knock-in mouse strain by inserting an IRES-Cre cassette 26 
nucleotides downstream of the stop codon present within coding exon 13 of the Trpc1 gene. 
The presence of an IRES element causes transcription of a bicistronic mRNA under control of 
the endogenous TRPC1 promoter, which is translated into two independent proteins, TRPC1 
and Cre recombinase within the same cell. For the characterization of Trpc1-expressing cells, 
homozygous Trpc1-IC mice have been bred with the reporter mouse strain eROSA26-GFP 
(Wen et al., 2011) to obtain double knock-in Trpc1-IC/eR26-GFP mice. The Cre recombinase 
present in Trpc1-expressing cells, deletes the transcriptional termination signal dubbed 
“STOP” in Figure 3-10. As a consequence, the DNA of the green fluorescent protein will be 
expressed under control of the ROSA26 promoter. The ROSA26 (R26) locus is ubiquitously 
expressed. The efficiency of the R26 promoter has been enhanced by introducing a so called 
CAGS fragment based the on chicken-β-actin promoter and cytomegalovirus (CMV) enhancer 
(Wen et al., 2011). Once switched on by Cre-dependent recombination, the green 
fluorescence exclusively depends on the eR26 locus. In the absence of Cre-mediated 
recombination, the transcriptional termination signal “STOP” flanked by two loxP sites, 
prevents transcription of the GFP DNA. Other reporter mouse strains (Wyatt et al., 2017) 
carrying yellow or red fluorescent protein, can be bred with the TRPC1-IC mouse.  
This binary genetic approach leads to the amplification of the fluorescent signal and thereby 
visualizesTrpc1-expressing cells. Other strategies involve the fusion of the fluorescent protein 
DNA as an IRES cassette: Like expression of the IRES-Cre cassette in the TRPC1-IC mouse, the 
expression of the IRES GFP cassette would be under the control of the TRPC1 promoter. 
Considering a very low expression level of TRPC1, the GFP expression would also very low and 
the fluorescent signal would be difficult to be detected using the later approach. In the current 
approach, fluorophore and Cre recombinase are expressed from two independent promotors: 





summary, Trpc1-IC KI mouse strain is a step towards solving the expression profile of the Trpc1 
gene. 
In ongoing experiments, we, my colleague Dr. Hongmei Wang and myself, have visualized 
TRPC1 expressing cells in the pituitary after breeding the Trpc1-IC and the eROSA26-GFP 
mouse lines. Single green cells and non-green cells were isolated and checked for the 
expression of Trpc1. All green cells and very low non-green cells do express Trpc1 transcripts 
(manuscript submitted). Apparently, the green fluorescence of the “non-green” cells 
expressing Trpc1 might escape our detection. Overall, these experiments demonstrate the 


















4.3 Generation of a conditional Trpc1 mouse strain 
In addition to the Trpc1-IC strain, I generated a mouse line carrying a conditional Trpc1 allele 
that functions as a wild-type allele in an undeleted state or as a null allele upon Cre-mediated 
excision. In 2007, Dietrich et al. described the generation of a global Trpc1 knockout by 
deleting the coding exon 8, supposedly involved in the formation of a pore region (Dietrich et 
al., 2007). This global Trpc1 gene-deficient model has been studied to characterize the role of 
TRPC1 in working memory formation (Broker-Lai et al., 2017), salivary fluid secretions 
(Ambudkar, 2014), in hemodynamic stress and cardiac hypertrophy (Seth et al., 2009), 
osteoclastogenesis and bone architecture (Ong et al., 2013). However, by the global TRPC1 
knockout, it is difficult to determine the role of TRPC1 in specific cells or organs. Therefore, it 
was in high demand to generate a conditional Trpc1 mouse model enabling to study the cell-
specific role of Trpc1 without interfering with the expression of Trpc1 in other cells. 
For the generation of a conditional Trpc1 mouse strain, we first wanted to insert loxP sites up-
stream of exon seven and downstream of exon eight. However, because of presence of 
repetitive nucleic acid sequences we abandoned that targeting strategy. As an alternative 
strategy, exon two was flanked by loxP sites. The resulting targeting vector was electroporated 
into ES cells. The ES cells were selected and the homologous recombination in ES cells 
heterozygous for the mutation was proven by PCR and Southern blotting.  We performed 
three independent set of trials by injecting six different ES cell clones at IBF, Heidelberg in 
cooperation with Prof. Dr. Marc Freichel and at iTL (New York, USA). From three independent 
clones we received 14 chimeras at IBF, with the chimerism percentage based on coat color 
distribution varies between 10-90%. We set different breedings in order to get F1 mice i.e. 
germline transmission but remained unsuccessful. The reason for this ordeal remained 
unknown. However, we remained successful in obtaining chimeras and subsequently F1 mice 
at iTL from three independent ES cell clones (supplementary Table 6-7).  With these F1 mice 
carrying the conditional allele, it is possible to obtain mice carrying a Trpc1 floxed allele by Flp 
recombinase activity and/or a Trpc1 L1F1 allele upon Cre-recombinase activity (Figure 3-17).  
Conditional gene targeting using a site-specific recombinase system i.e. Cre/loxP allows to 
delete the Trpc1 gene from any desired organ or a cell type at any time using a specific Cre-
recombinase expressing deleter mouse strains. It is based on the principle of breeding two 





Cre-recombinase in selected cell types or tissues. For instance, we have observed a trabecular 
bone phenotype and compromised osteoclastogenesis in our experiments performed on 
Trpc1-global knockout mice. For precisely defining the role of Trpc1 in osteoclast, deletion of 
Trpc1 specifically in osteoclasts is required using Cre-deleter strains which express the Cre-
recombinase gene under control of either TRAP or Cat K promoters (Chiu et al., 2004). The Osx 
(Osxterix)-Cre mouse strain can be used to delete Trpc1 specifically from the osteoblasts 
(Rodda and McMahon, 2006). However, endogenous skeletal defects such as delayed calvarial 
ossification have been identified in Osx-Cre deleter mice; making these mice not a good choice 
(Huang and Olsen, 2015).  
In summary, the conditional Trpc1 mouse strain will be useful for the deletion of the Trpc1 
gene in a spatially restricted or/and temporally restricted way. Our knowledge from studies 
with Trpc1 global knockout mice and our new studies with the Trpc1-IRES-Cre mouse have 
been shown the involvement of TRPC1 in different cells serving different functions. Studies 
with the conditional Trpc1 strain will complement this work and allow to dissect Trpc1 function 
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6 Supplementary data and information 
 
 
Figure 6-1 Comparison of weight between two strains of wild-type mice. Comparison of 
weight (grams, g) of 20-week-old male wild-type mice of two genetic backgrounds i.e. B6 
strain, C57BL/6 and mixed strain, 129SvJ/C57BL/6 is shown. 'n' numbers of wild-type mice on 
B6 and mixed genetic backgrounds are seven and nine, respectively. Statistics: Mean ± SD, 
two-tailed unpaired student’s t-test, with the number of mice indicated in the bars. 
 
Figure 6-2 Comparison of weight before fracture and after the healing phase of wild-type, 
Trpc1-/-, Trpv6mt/mt and double mutant Trpc1-/-/Trpv6mt/mt mice. Comparison of weight 
(grams, g) at day 0 (before the surgical procedure) and at day 28 (after sacrificing the mice, 
still with the screws) of (A) WT (B) Trpc1-/- (C) Trpv6mt/mt and (D) Trpc1-/-/Trpv6mt/mt mice is 
shown. 'n' numbers of WT, Trpc1-/-, Trpv6mt/mt and Trpc1-/-/Trpv6mt/mt mice are 11, 10, 10, 10 
respectively.  




Figure 6-3 Biomechanical analyses of fractured 
femurs from 24-week-old male WT, Trpc1-/-, 
Trpv6mt/mt and double mutant Trpc1-/-
/Trpv6mt/mt mice. Bending stiffness (N/mm) of 
fractured femurs analyzed by a non-destructive 
three-point bending test. Data shown as mean ± 
SD, calculated by one-way ANOVA followed by 
Bonferroni multiple comparison test. Four 
different colored bars represent four different 
genotypes: WT (black), Trpc1-/-(green), 
Trpv6mt/mt(red) and Trpc1-/-/Trpv6mt/mt (blue) with ‘n’ representing number of femurs in each 
group are 11, 10, 10, and 10 respectively.  
 
 
Figure 6-4 Cloning steps for the construction of the targeting construct, pAR_11, to generate 
the Trpc1-IC KI mouse strain. Agarose gel electrophoresis images show preparation of (A) 
pAR_6 and pAR_7 by sequential restriction enzyme cut, firstly, plasmids treated with (+) or 
without (-) restriction enzymes NotI-HF and PvuI-HF. Second cut with AgeI to obtain expected 
fragment size of 2381 bp (pAR_6) and 5947 bp (pAR_7). (B) Vector pAR_8 (8320 bp) and 
fragment pKO_ICF (3444 bp), arrow, after cut with the enzyme AscI. (C) Vector pAR_9 (11763 
bp) and fragment pKOselect DTV840 (1190 bp), arrow, after cut with the enzymes NotI and 
RsrII, respectively. The signs + or – depict presence or absence of restriction enzymes in the 
reaction.   





Figure 6-5 Selection of periosteal and endosteal calluses for analyses. Schematic 
representation of (a) a 6.5 µm cross-section with the cortical bone and periosteal and 
endosteal callus regions, (b) manually selected callus regions highlighted in red delineating 
the cortical bone in white, and (c) ROI consisting of only callus tissue for analyses.        
 
Figure 6-6 Abandoned targeting strategy for the generation of conditional Trpc1 mouse strain 
by floxing the exons 8 and 9.   





Figure 6-7 RT-PCR of Trpc transcripts with total RNA of (A) immortalized human osteoblast 
like cells and (B) bone marrow derived-osteoclasts (top), and bone derived-osteoblasts 
(middle), mRNA from brain served as a control (bottom), Hprt1 was amplified as a positive 
control and water used a negative control.  





Figure 6-8 Femur length (A) and parameters of cortical- (B) and trabecular- (C) bone of wild-
type and Trpc1-/- 12-week-old male mice on C57BL/6 (B6) genetic background determined by 
µCT. Data are shown as mean ± SD, analyzed by two-tailed unpaired t-test (* indicates p-value 
< 0.05, ** p-value < 0.01). The two genotypes are indicated in black (wild-type, WT) and green 










Table 6-1 Tasklist (Final_cortical_tasklist_Ahsan.ctt) for the determination of cortical bone 
parameters 
 
Table 6-2 Tasklist (Bruker_cortical (TMD)_tasklist_AR.ctt) for the determination of cortical 
TMD 





Table 6-3 Tasklist (Final_trabecular_tasklist_Ahsan.ctt) for the determination of trabecular 
bone parameters 
 
 Table 6-4 Tasklist (Bruker_trabecular (BMD)_tasklist_AR.ctt) for the determination of 
trabecular BMD 





Table 6-5 Tasklist (AR_callus analysis_final.ctt) for the determination of callus tissue 
parameters. 
Table 6-6 Summary of injections performed in Interfakultäre Biomedizinische 
Forschungseinrichtung (IBF), Heidelberg University, and iTL for the generation of Trpc1-IC 
mouse strain. 
 
Table 6-7 Summary of injections performed in Interfakultäre Biomedizinische 












Number of F1 
mice 
13D2 100   1 (iTL) - 
13D3 86   -  
13B4 77   6 8 











Number of F1 
mice 
11D3 80   -  
12A4 69   -  
31D3 86   -  
32A1 79   1 (iTL) - 
31B2 71   -  
32D2 85   1   16 
31D4 75   5   7 
